https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/september-highlights-a-defined-path-from-enrollment-to-data-to-regulatory-submis-546ba70def50c57b 2026-09-23T16:54:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-issues-new-guidelines-on-fentanyl-related-crimes-clarifies-sentencing-stan-d40ab24fc3aaf703 2026-09-23T15:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmap-2027-addresses-the-future-of-pharmaceutical-manufacturing-and-packaging-a24f87902f85969a 2026-09-23T15:44:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-immunotherapy-stop-the-clock-on-type-1-diabetes-01c89bbc9df567f0 2026-09-23T15:42:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-aa00bf1f361ce5fe 2026-09-23T15:41:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-vs-pfizer-in-2027-one-is-a-much-better-place-to-park-your-pharmaceutic-4de0a023ca1e4643 2026-09-23T15:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/9-pharma-leaders-sound-alarm-bells-on-biotech-s-decline-in-europe-8cae6dd44987e769 2026-09-23T15:31:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/ubc-okanagan-boosts-biotech-growth-jobs-in-kelowna-b5445b438b22e3df 2026-09-23T15:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/covid-19-vaccination-vaccine-product-information-2f002a54e328b7a9 2026-09-23T15:24:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/jaguar-health-plunges-59-and-viking-therapeuti-db83db73d7dc3b68 2026-09-23T15:14:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/petroliferos-lobo-and-oz-studio-expand-trace-from-petroleum-into-pharmaceutical-d8b3b5494ab74d32 2026-09-23T15:06:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-safety-module-in-the-clinical-trials-information-system-ctis-50e683a4919aefce 2026-09-23T15:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/europe-s-pharma-chiefs-warn-bloc-is-losing-innovation-race-dd74789b50fb2c08 2026-09-23T14:56:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/students-fill-high-paying-biotech-jobs-7b177440d9c34a4e 2026-09-23T14:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/expres2ion-biotech-holding-ab-exprs2-secures-sek-19-3m-to-13-exercise-1-1-b1ec93da641bbb8d 2026-09-23T14:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-big-pharma-unites-amid-ringing-alarm-bells-of-continents-dominance-42c06e624a767769 2026-09-23T13:54:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/bit-bio-partners-with-miriamed-to-bring-human-cardiomyocytes-to-its-drug-discove-6dfc3ef16dd20840 2026-09-23T13:47:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-reaps-311m-series-e-to-feed-ambition-to-become-a-household-name-f72260477437e222 2026-09-23T13:47:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/flagship-gets-a-pentagon-contract-fcb7bac7859a0771 2026-09-23T13:38:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/maia-biotechnology-expands-pivotal-phase-3-thio-104-non-small-cell-lung-cancer-t-410cbc55b527a9d2 2026-09-23T13:32:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/jedco-innovation-to-boost-jordan-s-pharmaceutical-industry-expansion-competitive-60088197bf5af4b5 2026-09-23T13:29:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/public-mental-health-autumn-webinar-school-based-mental-health-interventions-9698cdb22343e0dc 2026-09-23T13:28:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/q-a-why-ndc-12-readiness-has-to-happen-before-day-one-b1cd27b1952015f8 2026-09-23T13:26:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/about-30-000-new-lung-cancer-cases-occur-yearly-in-spain-and-portugal-a-trial-ha-0bd639da70000348 2026-09-23T13:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concord-biotech-announces-1-1-bonus-share-issue-shareholders-to-get-one-free-sha-e452dcfda4d71e2b 2026-09-23T13:15:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/rbc-says-ai-weakness-appears-to-be-fueling-biotech-rally-f7ddd140c25173b3 2026-09-23T13:13:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-trial-of-aurn001-for-cornea-d5b3dd232e1b81b4 2026-09-23T13:09:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-d2d89fe7cfa4c511 2026-09-23T13:08:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/sweden-a-powerhouse-for-early-stage-innovation-32336554ff8d853f 2026-09-23T13:06:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-chief-tukaram-mundhe-welcomes-bollywood-actors-support-for-food-7704108b6ff5afbe 2026-09-23T13:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-yorkers-prescribed-generic-drugs-could-be-entitled-to-share-of-96m-settlemen-079f2f04be6ccf19 2026-09-23T13:05:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/class-4-medicines-defect-notification-b-braun-melsungen-ag-meropenem-1000-mg-pow-c017a279be305219 2026-09-23T13:00:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-men-joined-forces-at-a-biotech-firm-one-is-being-hailed-for-his-work-to-cure-b32648efcb588026 2026-09-23T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/main-sequence-backs-dementia-biotech-kinoxis-in-a-9-25m-round-1e029c7e02718a39 2026-09-23T12:53:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-tukaram-mundhe-led-fda-expands-food-safety-drive-to-schools-festival-ff43b1c3c042f5f4 2026-09-23T12:52:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-milan-2026-preview-key-themes-and-emerging-trends-64ad898e4b3525ce 2026-09-23T12:33:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-game-biotech-volatility-f2eafaf137ceaf88 2026-09-23T12:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-drug-formulation-designed-to-reach-lung-tumors-has-mexican-patent-protection-t-9a6226bbb164d9be 2026-09-23T12:29:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards-2ec5afb22e0bf892 2026-09-23T12:28:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oppenheimer-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-d07bac4ace81e494 2026-09-23T12:27:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-nasdaq-mbrx-lowers-warrant-price-while-stating-it-needs-trial-funding-37feb91e0c967f74 2026-09-23T12:25:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-anna-72c1ed32316517e8 2026-09-23T12:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-900b781ebb8e9b5b 2026-09-23T12:19:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-pharmaceutical-sector-faces-decline-amid-global-competition-87e90953660cdc78 2026-09-23T12:06:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-dc35a2b891936318 2026-09-23T12:00:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/williams-cystoscopic-injection-needle-6c20102f9f238606 2026-09-23T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/omniasecuretm-mri-surescantm-2d8833077cd38fa9 2026-09-23T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-target-biotech-volatility-4c2712f525e7e336 2026-09-23T11:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-1d5604d4a504007c 2026-09-23T11:39:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-why-biotech-s-recovery-could-still-have-further-to-310d1862d2e9b283 2026-09-23T11:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/viking-s-vk2735-shows-durable-weight-loss-with-less-frequent-maintenance-dosing-03f08420126a796f 2026-09-23T11:23:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/oppenheimer-initiates-collegium-pharmaceutical-stock-at-outperform-c9f41444cb0d0522 2026-09-23T11:19:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/scientists-are-testing-an-unexpected-new-weapon-against-screwworm-7d6cd17f448fee72 2026-09-23T11:00:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-expands-wastewater-surveillance-to-strengthen-early-warning-system-for-dan-cebf5a4b17395e76 2026-09-23T11:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-b6711b307932a822 2026-09-23T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/henlius-looks-to-us-biotech-for-global-tce-rights-in-amberstone-deal-61b48e357cb64d42 2026-09-23T10:35:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/jefferies-raises-amgen-stock-price-target-on-drug-trial-success-cc7e529ee5fe6e74 2026-09-23T10:21:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-christoph-weber-for-board-seat-eb5e783eba6901a0 2026-09-23T10:11:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-and-amberstone-biosciences-inc-enter-collaboration-fc21a4575dc1493d 2026-09-23T10:05:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-biotech-startup-enveda-doubles-in-value-to-2-billion-wsj-2a17d33df3769840 2026-09-23T10:03:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-statistics-user-engagement-plan-65fe5013a86b6246 2026-09-23T10:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-statistics-in-england-and-wales-62845a4d19ed888c 2026-09-23T10:00:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-ai-biotech-enveda-doubles-in-value-to-2-billion-a869218d6b806c02 2026-09-23T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/jimmy-kimmel-trolls-trump-s-allies-with-parody-pharmaceutical-ad-b474764485d9f9c8 2026-09-23T09:59:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyurethane-tubing-for-biotech-market-to-2035-biopharma-capacity-expansion-driv-2c9779b6fa8fae8d 2026-09-23T09:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776 2026-09-23T09:42:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/nine-european-pharma-chairs-warn-of-slow-agony-as-investment-slips-1254cc631db64b03 2026-09-23T09:22:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-and-ionis-report-positive-phase-iii-readout-for-ulefnersen-36ca2d60798ce8df 2026-09-23T09:22:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis-treatments-ed6a223fc4d8d0a9 2026-09-23T09:15:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/doustdar-on-plunging-share-price-reflects-level-of-confidence-in-the-company-and-73e26491eface571 2026-09-23T09:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-14-to-18-september-2026-e1fc284848d2c91c 2026-09-23T09:03:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d981698b76b6bbf6 2026-09-23T09:00:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745 2026-09-23T08:58:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-23T08:56:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/fullgoal-fund-management-co-ltd-fullgoal-hang-seng-biotech-index-etf-159132-sz-i-566836e7c8e4c8f8 2026-09-23T08:56:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/innovation-must-remain-at-the-heart-of-pandemic-prevention-preparedness-and-resp-3432662b985a1270 2026-09-23T08:22:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-issue-376-september-2026-d78aba8959192ee6 2026-09-23T08:19:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-leaders-bfa3f2c240dbd84f 2026-09-23T08:18:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/testo-at-cphi-2026-in-milan-digital-monitoring-for-the-pharmaceutical-industry-51206cd2f0198a2f 2026-09-23T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/redweiler-480g-red-punch-redweiler-480g-orange-redweiler-480g-cola-tcm-120-mega-f98b8409bad1dcce 2026-09-23T07:53:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-23T07:48:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/medienmitteilung-die-bevolkerung-erwartet-einen-besseren-zugang-zu-innovativen-m-f83c269f70b8021f 2026-09-23T07:14:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/anaconda-biomed-snares-56m-in-funding-for-endovascular-tech-ec4619246ad794d9 2026-09-23T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-lifts-clinical-hold-on-simufilam-for-tsc-related-epilepsy-study-eca3143a8c42883f 2026-09-23T06:54:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/barzolvolimab-meets-all-primary-and-key-secondary-endpoints-in-phase-3-csu-trial-aaa1c6a5ed41a8da 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/cbl-514-meets-primary-endpoint-in-phase-2-dercum-s-disease-trial-4aa1315c77b554dc 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-s-sefaxersen-meets-primary-endpoint-in-phase-3-igan-study-8446d6133f8aa4ca 2026-09-23T06:53:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/denmark-s-central-bank-sees-4-gdp-growth-in-2026-boosted-by-pharmaceutical-indus-ae01f315cf303771 2026-09-23T06:44:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/wednesday-newspaper-round-up-state-pension-pharmaceutical-companies-bmw-22f669ea94e5958f 2026-09-23T06:05:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-kidney-disease-can-progress-to-kidney-failure-in-up-to-half-of-patients-within-b504c1b48ca0f4bd 2026-09-23T05:53:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/argenx-arrowhead-incyte-and-other-moonshot-biotech-stocks-to-watch-6bcfcd137294b001 2026-09-23T05:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-stained-ice-found-at-gallops-in-mumbai-restaurant-deepika-padukone-hosted-d7c8d4be6fe7ad46 2026-09-23T05:41:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-unveils-new-initiatives-to-reduce-animal-testing-in-drug-development-dcfb867919371bdd 2026-09-23T05:18:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-18f5014a922c38ad 2026-09-23T05:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-for-board-seat-904ade392ec97c62 2026-09-23T05:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-2d42ea33dec63e93 2026-09-23T05:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/change-in-roche-s-board-of-directors-3f66dadd4f0ce683 2026-09-23T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-217f74a05b95f6c6 2026-09-23T04:53:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-31a60ba7548325a7 2026-09-23T04:53:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/varda-space-industries-signs-steve-layne-as-chief-revenue-officer-and-aaron-hube-c7f0826d164cee9b 2026-09-23T04:37:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-surging-biotech-sector-represents-both-competition-and-lifeline-for-the-3c127d71cc0c9a1e 2026-09-23T04:23:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-clinical-trials-give-biotech-edge-us-concerns-grow-news-and-statistics-0f3c5f350061d556 2026-09-23T04:03:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-is-one-area-where-the-us-can-afford-to-let-china-flourish-804a8a8a2ecb3155 2026-09-23T04:00:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/guggenheim-names-top-stock-pick-in-biotech-sector-b71fce6a39b3f0f4 2026-09-23T03:49:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pca-girls-varsity-volleyball-vs-biotech-senior-32c8f64109110091 2026-09-23T03:45:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-share-market-update-pharmaceutical-stocks-surge-broadly-cansino-biologics-rise-8cc39d37a45eb156 2026-09-23T03:40:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/tailwind-biotech-wins-dkk-0-7m-innobooster-grant-9b2a13b8bb0fe6d2 2026-09-23T03:11:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fake-drug-case-pfizer-issues-statement-after-fda-revokes-licenses-of-1-21bf72b4a7e780a2 2026-09-23T03:05:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/better-healthcare-etf-invesco-s-biotech-focused-ibbq-vs-ishares-broad-iyh-cf62d79b13533fb7 2026-09-23T03:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dementia-biotech-kinoxis-raises-6-75-million-with-a-2-5m-grant-as-cherry-on-top-75874c1badfd9fdd 2026-09-23T02:44:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/jeil-pharmaceutical-s-onconic-begins-phase-3-trial-in-china-for-jaqubo-injectabl-fc3a04ac114cee7e 2026-09-23T02:40:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-4359a68ab4882f23 2026-09-23T02:20:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-fda-suspends-five-food-licences-after-finding-fake-ghee-cockroaches-blood-89c6ba90f7452325 2026-09-23T02:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-clinical-trials-about-to-become-a-new-front-in-the-us-china-biotech-race-4d06a653e66fe2bd 2026-09-23T02:00:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmac-opens-recruitment-for-new-community-and-patient-advisory-committee-2a31f0e2b8d9a966 2026-09-23T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-s-zastaprazan-enters-phase-3-injectable-trial-in-china-c9376c3ab0540be3 2026-09-23T01:53:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-says-patient-safety-top-priority-amid-karnataka-fake-drug-probe-6fdf8d6d60f6d15c 2026-09-23T01:52:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/young-discusses-national-security-threats-at-fdd-5b739c7bae264418 2026-09-23T00:35:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-therapeutics-launches-phase-3-clinical-trial-for-zaqubo-injectable-in-ch-5441eaf5cd51f86a 2026-09-23T00:14:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-advances-ja-q-bo-in-china-as-phase-3-injection-starts-royalties-rise-cho-b856b83f3cc2b983 2026-09-23T00:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-16511f0f2ac5ad4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-01b3e887f7dcead6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-4f5db2d73dc985cf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-10eeac13aab4c900 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f0eb7c639e6b7279 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5670169091ce7e56 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-eb184b78eb884466 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a093b591c8c1e790 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a5a2a3d18b030167 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-d97c25ec03b97152 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a92fc304b3f252b9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-735fad2b7cd0513d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-feeaac083dd2ed3b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-829dd417dc97be75 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-96e00503aecd8ab9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-temporary-moratoria-on-certain-agent-5d843f42db06f8b8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-9d0893d801a68de3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-closed-meeting-1fac41b8e10220fb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-bc642d60aa107458 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sanjay-kumar-final-debarment-order-b205422749fd0e88 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-4-hydroxy-n-n-diisopropyltryptam-4e3caa3036ced2d5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carson-valley-health-becomes-cleveland-clinic-connected-member-174093ab24c60298 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-pharmaceuticals-phase-3-kidney-trial-meets-proteinuria-endpoint-a1f79eed08f46dc9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-biochemical-responses-to-sglt2-sodium-glucose-cotransporter-2-inhib-7adc369689ad7377 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/digital-blueprint-to-traditional-craftsmanship-rehabilitation-of-atraumatic-maxi-b15c1c90f65e1e61 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/coping-strategies-among-early-phase-cancer-clinical-trial-participants-6d40b1b740992c12 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-impact-of-pharmacist-involvement-in-antimicrobial-steward-b6da4337dc8c16fc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kidney-transplantation-in-patients-over-80-years-of-age-clinical-opportunity-eth-609ac733fe0515e3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trefoil-technique-in-cryoballoon-isolation-of-the-left-common-pulmonary-vein-tru-9ab9b4bb159c12bf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-fortified-date-bar-on-perceived-stress-and-morning-salivary-cort-795cb59bd9f91736 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neck-disability-associated-factors-and-quality-of-life-among-physiotherapists-in-49a201e66e78e7eb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/postoperative-c-reactive-protein-as-a-marker-of-the-early-inflammatory-response-875ae85d2ce71266 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-safety-of-gastric-endoscopic-submucosal-dissection-in-patients-aged-8-4db1fa7ffa8f382b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multidimensional-assessment-of-cardiometabolic-risk-in-asian-americans-with-ch-03ad6b21bec4495c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/general-hiv-related-knowledge-and-attitudes-among-nurses-and-nursing-students-a-c6efa7106a99e37c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannabinoids-in-diabetes-integrating-scientometric-trends-with-mechanistic-pharm-39278e405c2b26f7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrative-analysis-of-atp2b4-expression-and-its-clinical-and-molecular-associa-930117645916a86d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-acquisition-quantifying-the-annual-carrying-cost-of-long-term-biospecimen-b9123924b47e7a6c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paraprobiotics-and-postbiotics-from-mechanistic-evidence-to-food-applications-an-8f9399cd6bdd47cc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-explainable-artificial-intelligence-for-trustworthy-and-human-centric-ac82feba19738eaa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-role-stress-and-job-burnout-among-clinical-research-nurses-a-b5aa08fccae4bfd4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapist-self-report-reliability-and-accuracy-in-individual-vs-conjoint-systemi-e555b020dd335edd 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimal-prophylaxis-for-perioperative-drug-induced-delayed-neurocognitive-recove-5ca2615ca4e7f295 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-clinical-outcomes-associated-with-a-standardized-multicomponent-facia-e1801e946690bdbb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-anticoagulation-therapy-in-elderly-patients-with-clinically-diagnose-de416e1a65baf3d8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multimodal-machine-learning-diagnostic-model-for-alzheimer-s-disease-integrati-226cd8e46b6e3b46 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biological-characterization-of-a-clinical-human-adenovirus-type-3-isolate-with-o-cdfc8156c517f734 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-cohort-study-predictive-nomogram-for-clinical-pregnancy-outcomes-3525205333fa2902 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-early-enteral-nutrition-support-on-gastrointestinal-function-abe6b8b27c7ff208 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities-fo-f6f882b45b14e4b6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-epidemiological-profile-of-hospitalized-patients-with-leptospirosis-b7104dcb13cec58b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/metabolic-and-anthropometric-predictors-of-paediatric-metabolic-steatotic-liver-c04828fdbc62dda2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-efficacy-of-whole-body-chlorhexidine-gluconate-cleansingwith-or-witho-bf1520c4fa2ebd4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uptake-barriers-and-facilitators-of-open-science-in-clinical-psychology-findings-e79006e53d98c6de 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-care-contributes-to-tuberculosis-treatment-adherence-and-drug-saf-c97458518d1fd4b2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-review-of-nanostructured-lipid-carriers-nlcs-and-their-applications-in-pharmac-4190dcc03c58cab9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-optimization-of-an-rt-qpcr-assay-for-determining-mirna-1202-expr-f465d5014a63c6eb 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/addictive-escapism-in-the-context-of-fragmentation-of-value-semantic-space-drug-39c30a45b7c82bb5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peer-review-report-for-effect-of-a-community-based-intervention-for-cardiovascul-bffd3e087f4f828c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-timing-of-presentation-and-laparoscopic-findings-on-clinical-outcomes-99b32a220658c2ef 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-aimsi-protocol-study-protocol-of-a-randomized-double-blind-non-inferiority-c-0d2f973c86632267 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-four-tier-anti-hcv-hcv-rna-interpretation-grid-for-risk-selected-clinical-popu-0462e6238c73bb27 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immediate-analgesic-effect-of-cheek-acupuncture-vs-etoricoxib-for-patients-with-1f433045c616e8d5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/recombinase-polymerase-amplification-coupled-with-crispr-cas12a-for-rapid-detect-9088f98caabcd613 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/polygenic-risk-score-enhances-comprehensive-breast-cancer-risk-assessment-and-mo-f105e2006792438e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-status-influences-circulating-microrna-expression-and-their-clinical-a-330230b34efa50ae 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-species-composition-and-antimicrobial-res-ad48db0c75ecfcad 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cell-free-therapies-emerging-applications-of-extracellular-vesicles-and-secretom-0eb0c307fb10fd9d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/legal-organizational-and-financial-mechanisms-for-providing-medicines-not-includ-adcb8486b171831b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leveraging-long-read-sequencing-to-bridge-the-diagnostic-and-equity-gaps-in-diff-e2cbefef207ca413 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-from-y-lmaz-et-al-the-free-t3-free-t4-ratio-predicts-relaps-73b9efa36fc223a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dna-methylation-dysregulation-in-ebv-associated-lymphoproliferative-disorders-mo-5a356c91440576fd 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-note-on-patient-follow-up-time-distribution-in-clinical-trial-simulations-with-d0133161e4e00572 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-treatments-and-outcomes-of-patients-with-ornithine-tran-a1c88d6d32ef3a51 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adherence-to-treat-to-target-recommendations-in-juvenile-idiopathic-arthritis-in-84176e3cd58018ed 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precise-repair-of-extremity-soft-tissue-defects-using-anterolateral-thigh-flaps-ec30ab4fc6df8f00 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-clinical-need-socioeconomic-inequalities-in-access-to-hospital-at-home-am-7c521189ed269087 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/i-invited-commentary-on-i-kandathil-et-al-s-postoperative-pain-management-in-rhi-658daec99b991957 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenolic-mannich-bases-review-on-synthetic-aspects-and-biological-activity-profi-61a6f71ecb860f68 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/red-blood-cell-aggregation-and-atherosclerosis-curvilinear-clinical-implications-ef768b300cdbacbe 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-eating-disorders-in-relation-to-premenstrual-syndrome-in-adolescen-c0244b80e5002d85 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/defining-near-term-treatment-goals-for-benzodiazepine-use-in-clinical-practice-04a3e19325e3d4f7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-next-frontier-in-quantitative-co-clinical-imaging-to-advance-functional-prec-ee218ea96855a1a9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-utility-of-whole-genome-sequencing-in-identifying-a-rare-i-mycobacteriu-94f0e27ffb6f1678 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-and-mechanisms-of-scp-ziyushuang-scp-an-anti-skin-aging-formul-dcb5b530a46d9958 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-ambient-digital-scribe-systems-in-clinical-documentati-7e52ee06c03a15d9 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reduced-antibiotic-exposure-is-not-equivalent-to-reduced-antibiotic-overuse-afte-befc1cf0c44de4bf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fully-ablative-co2-laser-excision-of-cutaneous-lesions-a-case-series-including-p-61eadbc7ce6135fa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tolerance-of-methotrexate-co-administered-with-pegloticase-in-patients-with-unco-7f3259a1243d82b3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-benefit-of-routine-pet-ct-imaging-in-asymptomatic-head-and-neck-squ-a01c2272b379ada0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practical-lessons-in-the-global-scaling-of-clinical-ai-from-one-hospital-to-over-d823dc98459196b5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-and-mucosal-antibody-responses-against-neisseria-gonorrhoeae-ng-outer-m-7a0211afbe545718 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-efficacy-and-safety-of-cd19-chimeric-antigen-receptor-t-cell-therapy-bc4ebc4c756dba65 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synthetic-lethality-in-cancer-mechanisms-therapeutic-exploitation-and-clinical-t-1f3bebf9bae27ae3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asymmetrical-consent-in-ambient-clinical-ai-rethinking-patient-recording-rights-e70ad24154760143 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/carotid-intima-media-thickness-in-beta-thalassemia-a-systematic-review-and-meta-305f74b84c51fd60 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predictors-of-morbidity-and-mortality-in-malignancy-related-ascitic-fluid-infect-d88edb300cf290a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacotherapy-of-irritable-bowel-syndrome-with-constipation-in-children-an-upd-afbf506f2debfc3c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-preoperative-pain-neuroscience-education-on-pain-catastrophizing-and-e-421cbac901807b13 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-patient-reported-outcome-measurement-in-fibromyalgia-clinical-trials-a645cfade04ad851 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/professional-socialization-and-competency-based-role-development-in-clinical-eth-8af2a02fe55fbcbc 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agentic-ai-in-medicine-challenges-for-responsible-development-and-the-case-for-c-26ffe98b6e3b2465 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-status-over-chronology-determinants-of-curative-versus-palliative-tr-13b5296c766e71c2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/improving-adaptation-in-male-high-altitude-workers-through-pressurization-a-rand-5bafac1786fd222c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ranibizumab-port-delivery-system-for-neovascular-age-related-macular-degeneratio-d7aa2ef6ee7adaae 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procomb-a-practical-and-robust-design-with-randomization-to-optimize-dose-combin-290fbb808edc5459 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-sickle-cell-hemoglobin-genotypes-on-clinical-outcomes-among-i-plasmodi-d38e4ae0b0ee8c10 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-biological-mechanisms-to-causal-inference-quantitative-systems-pharmacology-3681a18664af4d7e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/volumetric-modulated-arc-therapy-for-lung-cancer-correlation-between-dose-and-vo-6490752166bf0195 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transvaginal-drainage-vs-laparoscopy-for-tubo-ovarian-abscess-6cbf99995376ed2c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837336-an-evaluation-of-nutritional-status-body-composition-and-dietary-int-ac0a45c501a1eb6d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07837089-increasing-engagement-with-digital-behavioral-health-ef6671fec5e10550 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836764-validation-of-1-minute-sit-to-stand-test-for-assessment-of-breathles-8859db9c2c87a48e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836738-effect-of-stellate-ganglion-block-on-sleep-quality-in-patients-with-5b8e8e776e4c1c8d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836686-clinical-and-radiographic-success-of-modified-lstr-techniques-in-pri-6cb9d89901a63027 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836452-a-phase-1-first-in-human-study-of-city-rbp4-in-healthy-volunteers-an-37c0c1ff6e99544a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836439-comparing-graston-technique-and-diacutaneous-fibrolysis-for-pain-dis-e09cd2476cb3651f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836205-brain-activity-and-changes-in-consciousness-during-general-anesthesi-b453ee4141f9c01a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836101-study-of-sarilumab-with-immune-checkpoint-inhibitor-rechallenge-in-p-2356a03863440eaa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836088-a-clinical-study-on-using-multimodal-ultrasound-to-assess-muscle-mas-7d4fef44519e2a4f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07836036-evaluation-of-ras-inhibitor-treatment-in-participants-with-advanced-97efdfb4531195db 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07835997-radicle-relaxationtm-cix-a-study-assessing-the-impact-of-health-and-934bffecad7e6f1a 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07835945-comparison-of-arterial-and-capillary-blood-gas-analyses-in-patients-529f238adbd0acd5 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830212-diagnostic-performance-of-acp3-targeted-pet-imaging-in-patients-with-565d43acb3c87207 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830173-effects-of-task-oriented-training-on-balance-with-or-without-texture-3015b6561b54636c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07825857-randomized-controlled-trial-of-tirzepatide-for-methamphetamine-use-d-23e6cd17cc91d8df 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07678606-association-between-4d-mri-parameters-and-the-clinical-characteristi-96a7cb0cf013b2e6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07661810-patient-controlled-remimazolam-sedation-under-spinal-anesthesia-137f2a8674e26ee0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07643922-endovascular-therapy-for-cerebral-vasospasm-after-aneurysmal-subarac-8f6d74f8cf9d0947 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07631377-the-lalelalung-study-digital-stethoscope-clinical-evaluation-beb6ad86a49511a4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07610395-trial-comparing-the-safety-and-efficacy-of-two-different-oral-vpv-do-87a303f89eb88c16 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07549321-a-safety-and-efficacy-study-of-hu14-in-high-risk-neuroblastoma-patie-43b06e17d6f6ecf0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07530705-efficacy-and-safety-of-subcutaneous-injection-of-xh-02-in-the-treatm-f412cd4960e5cf43 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07527052-emerging-technologies-and-teen-mental-health-1ddeb4440ccb88cf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07522944-ai-guided-personalized-relaxation-for-hemodialysis-patients-a62638bab807b3f4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07518407-dietary-insights-and-nutritional-education-in-adults-on-glp-1-therap-4dec0f2fe0a882e7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07502352-remotely-delivered-cognitive-behavioral-stress-management-for-breast-91150ea8bc706ee0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07343024-methods-of-identifying-effective-off-guideline-treatments-for-advanc-ca2a1b38930bebd7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07242300-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-fo-045a31d11416acd0 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07237295-communityrx-kidney-health-d9146459a64c0ff2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07225075-pivotal-study-of-the-silk-vista-baby-flow-diverters-in-the-treatment-bc87ac8f8819f15d 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07169630-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-ad9bf3a66aac9969 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07156175-a-study-to-investigate-the-efficacy-and-safety-of-sar444336-in-adult-b02814ea75fb9a86 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07094412-patient-engaged-development-and-testing-of-educational-content-on-si-27ba66199a75081e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07087249-feasibility-and-preliminary-effects-of-a-therapeutic-approach-using-d219d987db0fd1a3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07005297-clinical-genetics-branch-eligibility-screening-survey-e7dec4054d0f1b0f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06926283-a-study-of-dxc008-in-patients-with-prostate-cancer-and-other-solid-t-2fa107a99237b6d4 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06922786-hemadsorption-to-enhance-drug-elimination-in-intoxications-84ac6507d560994b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06878066-thrombolysis-in-factor-xa-inhibitors-trial-3f17a0f3421a802b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06824987-dose-ranging-safety-tolerability-and-efficacy-study-of-azd2373-in-pa-92b855aa8d4ba3fa 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06774885-role-of-folic-acid-in-the-management-of-adjuvant-endocrine-therapy-i-417f6298e18d101c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06659341-a-phase-i-study-of-bay3498264-given-together-with-sotorasib-in-parti-85034d93db98e407 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06633536-real-life-treatment-outcomes-of-ravulizumab-in-pnh-2cd6c195b7a76415 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06630013-a-new-ultrasound-score-for-swallowing-disorders-diagnosis-in-difficu-abb34b6abc54acc3 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06619587-a-study-to-evaluate-safety-pharmacokinetics-and-activity-of-gdc-7035-31c0e9a9b3d7a2cf 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06558214-optimus-prime-safety-and-feasibility-of-optune-gio-integrated-with-m-c4f3b9d8c7fc609e 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06500702-a-study-to-evaluate-the-efficacy-and-safety-of-frexalimab-brivekimig-e8eca76edaae6e69 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06389591-rna-lipid-particle-rna-lp-vaccines-for-recurrent-adult-glioblastoma-93050016a66deac6 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06305676-biomarker-approach-to-screening-for-the-early-detection-of-hpv-relat-104230ccfe36130b 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06014489-a-trial-to-assess-cobicistat-boosted-venetoclax-in-combination-with-e7d8687b4e0bc8c2 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05624528-a-clinical-trial-of-tolcapone-in-obsessive-compulsive-disorder-6738dd1b07616e6f 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04989504-testing-the-application-of-mepitel-film-during-radiation-therapy-to-a505af7d533aa90c 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04812925-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-efgartigimod-caa7445c3958c388 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04628767-testing-the-addition-of-medi4736-durvalumab-to-chemotherapy-before-s-d432900cd209dde8 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04591639-the-dapa-memri-trial-9f8a6fec825fbaa7 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04433455-influencing-factors-of-cerebrovascular-disease-and-cognition-in-hemo-430cbbfd790ca1de 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04400695-a-study-of-rc48-adc-for-the-treatment-of-locally-advanced-or-metasta-e349c8a3a71c2f58 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04222413-metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors-fba3643f3c2c4144 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02444936-zostavax-in-persons-imminently-receiving-chemotherapy-for-solid-orga-ddb176532249fbec 2026-09-23T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-s-7185c26cdd11880d 2026-09-22T23:52:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/keep-britain-working-review-update-a-national-growth-opportunity-september-2026-b449a68a7ec408e5 2026-09-22T23:01:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/as-stigma-fades-reverse-mergers-boom-in-biotech-174a6012d4b759f8 2026-09-22T22:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-takes-issue-with-empower-pharmacy-s-glp-1-production-in-new-warning-letter-bbcc7bc0792288c1 2026-09-22T22:48:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-overlooked-role-of-containers-in-chemical-and-pharmaceutical-operations-d9a479d7a99df2f6 2026-09-22T22:09:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-pharmaceutical-manufacturing-facility-9c9b191a0f0915cd 2026-09-22T21:44:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-s-yipin-pharmaceutical-raises-tens-of-millions-in-yuan-for-anaesthetics-pu-df3f73952434bb15 2026-09-22T21:18:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/biopharma-biological-safety-cabinets-aseptic-technique-for-sterile-drug-manufact-50ac51026318a92a 2026-09-22T20:51:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/vht-vs-xbi-is-diversified-healthcare-exposure-or-biotech-stocks-the-smarter-choi-0db424becee8ba71 2026-09-22T20:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-drug-meets-goals-of-key-test-in-common-autoimmune-disease-with-no-approved-562c53f4bdd9952b 2026-09-22T20:03:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/human-cell-tests-and-computer-models-gain-formal-place-in-fda-rules-for-drug-saf-4288d02f95194a5d 2026-09-22T20:00:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-therapeutics-upgraded-to-buy-after-posi-03401a823e3c1eb5 2026-09-22T19:59:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-a-precision-medicine-trial-leveraging-blood-based-tumor-genomics-832a33c89b017818 2026-09-22T19:58:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-african-vaccine-initiative-eavi-accelerating-preventive-450f5665b25341fd 2026-09-22T19:55:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-services-for-environmental-exposure-and-health-assessment-in-euro-53b48a7be88525ab 2026-09-22T19:54:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/on-the-job-training-program-helps-greenwood-resident-into-biotech-career-811eb59219a9358c 2026-09-22T19:53:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/direxion-daily-s-p-biotech-bear-3x-shares-declares-quarterly-distribution-of-0-0-ccfddfb80ed3a79a 2026-09-22T19:52:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ulefnersen-meets-primary-end-point-in-phase-3-fusion-trial-for-fus-als-004c41caee9d8e4e 2026-09-22T19:41:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-shareholder-plans-2-715-ads-rule-144-sale-841a12d86e050982 2026-09-22T19:31:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-reports-a-phase-3-win-with-sjogren-s-drug-candidate-4d19987a7b90f4bd 2026-09-22T19:06:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-nj-pharmaceutical-company-lays-off-hundreds-9bb21c3e4fe5cb52 2026-09-22T19:03:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/nine-european-drugmakers-note-concern-over-region-s-pharma-investments-pharmexec-d2f1bdf40f76425d 2026-09-22T19:02:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-drugmakers-say-they-are-losing-ground-to-us-and-chinese-rivals-0d402f8f3ef33843 2026-09-22T18:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-legend-biotech-nasdaq-legn-officer-lines-up-1-3m-stock-sale-a09773669bac8e93 2026-09-22T18:34:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-f355446610826911 2026-09-22T18:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/did-ceo-appointment-just-shift-legend-biotech-stock-investment-narrative-39b39a15e61896b9 2026-09-22T18:06:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/caris-life-sciences-coasts-past-a-buy-point-why-this-texas-biotech-researcher-de-bc7b2a82a6bfdea0 2026-09-22T18:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-rules-to-advance-non-animal-innovative-testing-in-human-drug-develop-c6422f067acfdab8 2026-09-22T17:47:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-secures-new-radioligand-in-900m-deal-as-competition-strengthens-50d67d023b86cc61 2026-09-22T17:22:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-representative-clinical-research-advancing-inclusivity-in-europe-ce5cc956533fb572 2026-09-22T17:18:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-suspends-assistant-drug-controller-over-alleged-lapses-in-counterfeit-954ba4d2ecda5f99 2026-09-22T17:01:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-an-innovative-analytical-platform-to-investigate-the-effect-and-t-22d02dfce8336ab4 2026-09-22T16:48:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-autism-innovative-medicine-studies-2-trials-36292d3d44288306 2026-09-22T16:48:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-s-kidney-drug-success-sparks-a-22-surge-for-this-rival-biotech-860d4568cb022503 2026-09-22T16:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-modernizes-drug-regulations-to-formalize-support-for-nams-7dde384d2183288c 2026-09-22T16:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-medicine-racket-assistant-drug-controller-omkareshwar-suspended-aa6b284cdda1363b 2026-09-22T15:57:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-rule-on-animal-testing-for-new-drugs-98a07a874a31de1b 2026-09-22T15:52:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/food-drug-crackdowns-test-india-s-regulatory-enforcement-muscle-ba2109dbf55a7346 2026-09-22T15:48:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-drug-safety-testing-rules-to-embrace-non-animal-methods-cedfedd050abc998 2026-09-22T15:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/generic-drug-user-fee-reauthorization-amidst-alleged-concerns-of-safety-and-effi-c661778b45f1c06e 2026-09-22T15:38:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-participates-in-ustr-s-section-301-investigation-into-germany-to-address-e44e409ff6d1d1c8 2026-09-22T15:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-temperature-control-is-now-pharma-s-make-or-break-variable-0b39008986dae1a7 2026-09-22T15:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-otsuka-s-phase-3-win-in-als-subtype-boehringer-s-up-to-1b-cancer-deal-c9153ce71a34dadf 2026-09-22T15:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rs-5-05-crore-spurious-drug-racket-case-24-pharma-licences-16-cancelled-and-8-su-2a0c3f8f2c032d62 2026-09-22T15:20:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/zealand-pharma-announces-initiation-of-the-registrational-phase-3-zupreme-progra-478c3cbbf4c8be0c 2026-09-22T15:15:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-inc-stock-amgn-moved-up-by-3-90-on-sep-22-facts-behind-the-movement-638e1517a3957b7d 2026-09-22T15:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4 2026-09-22T15:06:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3 2026-09-22T15:00:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-reasons-to-have-your-flu-vaccine-when-pregnant-poster-617282f23f9f2cc4 2026-09-22T14:59:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2 2026-09-22T14:58:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20ce 2026-09-22T14:56:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-you-buy-moderna-stock-why-many-wall-street-analysts-say-no-9e67b14c2180f083 2026-09-22T14:53:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/4-biotech-stocks-with-key-clinical-readouts-expected-this-fall-fdfbfae8d3ac9708 2026-09-22T14:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-backed-iambic-files-for-ipo-disclosing-new-clinic-and-dealmaking-details-9081c31813b92024 2026-09-22T14:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge-program-0be7d11290c417d3 2026-09-22T14:26:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-ipo-blitz-continues-with-4-new-biotech-filings-347251671248c048 2026-09-22T14:23:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-s-horizon-acquired-fusion-protein-eases-sjogren-s-severity-in-ph-3-win-fabca74fb5c275a3 2026-09-22T14:20:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-and-pace-make-new-bacteria-available-to-support-research-into-tackling-ant-03949b464e5bf1c5 2026-09-22T14:19:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-preliminary-positive-data-from-open-label-extension-of-phase-3-study-fasedie-a43f8824c131b981 2026-09-22T14:14:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-stakeholders-can-avert-340b-rebate-disruption-766ebeb8cd517505 2026-09-22T14:14:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-announces-positive-topline-results-from-phase-3-fusion-study-of-ulefnersen-772a4e1e1109bf31 2026-09-22T14:11:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-b70c8b2f7386a8a2 2026-09-22T14:11:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/travere-ceo-eric-dube-to-step-down-after-transforming-the-rare-disease-biotech-89bdf641a2b15d7c 2026-09-22T14:10:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-s-midstage-data-amplify-kidney-disease-market-opportunity-523fc055ccc416fc 2026-09-22T14:09:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64 2026-09-22T14:07:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-publishes-2026-food-code-c8977096a5309312 2026-09-22T14:07:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-sued-with-former-lot-network-canon-patent-by-biotech-npe-181c0bc7aa670f0e 2026-09-22T14:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/changes-to-the-definition-of-deprivation-of-liberty-6ef57301ec10516e 2026-09-22T13:52:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-is-ibogaine-all-about-the-psychoactive-drug-presley-gerber-took-for-treatme-10da3bcc8d406517 2026-09-22T13:52:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/x-chem-announces-phase-3-milestone-in-collaboration-with-relay-therapeutics-2ed0320843199e26 2026-09-22T13:51:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-the-classroom-to-research-rethinking-school-non-attendance-as-a-complex-pub-370891176b9691ed 2026-09-22T13:47:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-in-phase-2-diabetes-tri-456c0904bdf4161e 2026-09-22T13:42:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-s-dazodalibep-phase-3-trial-clears-sjogren-s-hurdle-ce20313f496b35b5 2026-09-22T13:32:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-proposed-law-could-give-qualifying-botanical-drugs-12-years-of-market-exclusiv-49f868a028738c3d 2026-09-22T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comienza-en-lisboa-el-xv-encuentro-de-la-red-eami-con-el-objetivo-de-establecer-a43077edfe8b6ead 2026-09-22T13:23:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-heads-to-fda-as-ionis-partnered-als-drug-hits-primary-phase-3-endpoint-7548c69d954fe247 2026-09-22T13:22:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/tb-bcg-and-your-baby-74fb0616222bda49 2026-09-22T13:05:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-announces-positive-topline-phase-3-results-for-dazodalibep-in-moderate-to-6063bc2e687b62fc 2026-09-22T13:05:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/sjogren-s-disease-has-no-fda-approved-medicines-amgen-s-treatment-improved-disea-be1c1e5896371af6 2026-09-22T13:02:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelic-depression-and-ptsd-trials-get-new-lead-at-optimi-health-opth-41c95a683e26fe4e 2026-09-22T13:00:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/optimi-health-appoints-dr-michael-blough-as-chief-clinical-development-officer-b962f1ca3661de64 2026-09-22T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-lung-cancer-treatment-showed-90-5-disease-control-in-an-interim-trial-assessme-65b591b14180f7f7 2026-09-22T12:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maia-biotechnology-reports-pivotal-phase-3-clinical-trial-progress-in-advanced-n-d50277e15a8ec3c4 2026-09-22T12:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preliminary-data-social-anxiety-scores-improved-31-points-in-four-months-with-vi-c63a4ba9a63823a2 2026-09-22T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/wisner-baum-investigates-generic-drug-quality-as-2026-patent-cliff-accelerates-c-579b2debb3e49258 2026-09-22T12:19:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-d5ff980a261f735c 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/claros-technologies-announces-continued-commercial-expansion-into-europe-and-ent-21dc3bd5985bea1b 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/allergan-aesthetics-debuts-aa-signaturetm-in-the-united-states-with-skin360-its-3fb68c46a13552f5 2026-09-22T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-rare-seizure-disorder-has-no-approved-treatments-a-trial-has-dosed-its-first-8857792eb4fd05eb 2026-09-22T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-depression-data-could-define-the-case-for-cybin-stock-bf3ee7c531131e23 2026-09-22T11:25:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-presents-h1-2026-results-and-provides-corporate-update-12c4c38dc6d0be1a 2026-09-22T11:24:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-reports-positive-phase-3-results-for-barzolvolimab-in-chronic-spontaneou-0017f5ea9d432ed0 2026-09-22T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/celldex-announces-positive-results-from-phase-3-embarq-csu1-c8dfd9af985de52b 2026-09-22T10:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-securities-names-top-biotech-stock-amid-sector-rally-65a732f8b3124bfc 2026-09-22T10:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-merck-drug-cut-the-risk-of-worsening-disease-by-76-the-fda-updated-its-label-35639d1ef2653d3e 2026-09-22T10:50:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-phenylephrine-hydrochloride-prices-hold-firm-as-q4-pharmaceutical-demand-stre-0149dcbbdb4b1dc3 2026-09-22T10:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-d63bea0d0db63aa3 2026-09-22T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-e2755dc1ca6275fc 2026-09-22T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-68a2c21adf64b7b1 2026-09-22T10:42:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f39731160de90db0 2026-09-22T10:37:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/nearly-600-fda-postmarket-drug-studies-are-behind-schedule-while-many-of-the-med-f28350f4fcac615b 2026-09-22T10:15:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-survey-a86c0a5b77beeed2 2026-09-22T10:00:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/harmoni-gi1-a-phase-iii-trial-featuring-ivonescimab-plus-chemotherapy-compared-t-5397d986a24a195a 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/direct-nitrite-analysis-simplifies-tests-of-pharmaceutical-excipients-for-risk-c-4b362d430ed610ea 2026-09-22T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-2b9ea682e34169f8 2026-09-22T09:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-round-up-22-september-2026-5ba9abe7a8a91f88 2026-09-22T09:23:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-corporation-mnkd-stock-analysis-exploring-a-127-68-potential-upside-in-88d42183e45cec68 2026-09-22T09:21:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/book-review-the-age-of-cures-by-barry-werth-50b9ec628976b5a2 2026-09-22T09:00:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-mil-taxotere-supply-deal-with-china-s-yifan-6f397d63d69e2daf 2026-09-22T08:37:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-director-pdmr-shareholding-bb695b3e1242f838 2026-09-22T08:32:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-and-university-of-oxford-scientists-uncover-genetic-changes-in-the-bacteri-619305ae10369373 2026-09-22T08:30:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2026-1002643f3a56701e 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-health-impacts-from-industrial-sources-of-pfas-a-rapid-review-ed4c661ce7265e41 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/per-and-polyfluoroalkyl-substances-pfas-general-information-49da969af76edf3b 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/vpag-quarterly-net-sales-and-payment-information-e87d48f3b7220662 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemical-hazards-compendium-2cf1a7b32dba1e24 2026-09-22T08:30:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanyang-precision-chairman-countersues-former-hanmi-pharmaceutical-executives-29f8aa0fd33812f7 2026-09-22T08:20:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-s-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sp-db564c899dadd3aa 2026-09-22T07:55:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/submicron-ir-for-pharmaceutical-research-development-and-quality-f91eaac67fdb6ecb 2026-09-22T07:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sant-98561788d726bcd6 2026-09-22T07:40:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/greece-to-prioritise-biosimilars-legislation-during-2027-eu-presidency-says-mini-7c952cb632ab6e86 2026-09-22T07:33:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-c8c0fec7c979c997 2026-09-22T07:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/iambic-maintains-momentum-from-string-of-big-pharma-partnerships-by-aiming-for-i-14246701c70fe37f 2026-09-22T07:14:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/trevi-therapeutics-stock-trades-at-usd-14-71-as-biotech-data-matters-663f1d5418a1fc34 2026-09-22T07:13:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-aspen-s-priyen-naidu-drives-a-human-centred-approach-to-technology-f2ab4450d8792b6a 2026-09-22T07:10:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/bank-of-america-corp-de-invests-38-35-million-in-ultragenyx-pharmaceutical-inc-r-127cbc20e446c4bf 2026-09-22T07:10:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/building-on-success-ipsen-receives-two-new-gold-brandon-hall-awards-d9486765e1c17bb8 2026-09-22T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimer-s-045429441a897961 2026-09-22T06:45:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia-ae296af74503e57a 2026-09-22T06:40:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-nonclinical-testing-regulations-140133928ca7c94d 2026-09-22T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411 2026-09-22T06:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-cadbbf2157ab9b29 2026-09-22T06:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-self-reliance-moment-102921bdf8bc7232 2026-09-22T05:50:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-best-glp-1-stocks-for-2026-and-how-to-invest-99408731658b95c2 2026-09-22T05:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-scores-277m-anti-cancer-drug-supply-deal-in-china-d65692bc15e5f4fc 2026-09-22T05:02:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-resu-ca3349841e8c60a5 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthnet-mea-to-commercialise-comide-er-methylphenidate-er-in-uae-under-exclusi-25f7252f14d192bd 2026-09-22T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/child-resistant-locking-closures-market-to-2035-pharmaceutical-safety-mandates-d-ee831d2ecb1081b6 2026-09-22T04:46:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-news-96d7107e3a341182 2026-09-22T04:26:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-finally-moves-to-comply-with-2022-law-ending-animal-testing-mandate-3c5286ce175b5ebd 2026-09-22T04:07:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-478bd63e265078d4 2026-09-22T03:35:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-moves-away-from-animal-testing-how-organoids-ai-organs-on-chips-could-imp-8ae12dc92c9fbd34 2026-09-22T03:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boryung-signs-277-million-taxotere-supply-deal-with-china-s-yifan-pharmaceutical-a71b4ed4f2241099 2026-09-22T03:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/melbourne-biotech-turns-to-stem-cell-brain-models-in-alzheimer-s-push-7ea3ae37b3c8e127 2026-09-22T02:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-strict-checks-on-drug-supply-chain-9e99b919fddbd074 2026-09-22T02:29:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524 2026-09-22T01:59:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-s-breast-cancer-combo-wins-approval-2625666fc10dfe92 2026-09-22T01:26:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-ultragenyx-pha-eb82ae5a7d95e0ef 2026-09-22T01:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-envista-holdin-90aff1940631b27a 2026-09-22T01:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-wellbeing-and-boryung-expand-korea-hospital-use-of-livnec-injection-chosunbiz-f8357be306326357 2026-09-22T00:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-details-phase-3-sleep-apnea-trial-for-ex-metsera-obesity-drug-9b66bc3b08304ba5 2026-09-22T00:38:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-l-d11a80ef91435ad7 2026-09-22T00:17:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60 2026-09-22T00:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-2122447c5946b5e1 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-cancer-institute-notice-of-meeting-8918f24bc0866cb9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e3d513e458366039 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-774090bba85bb2af 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nonclinical-testing-terminology-5eba25885ce1826a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-c3c6da23622a87ae 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-the-impact-and-costs-of-promoti-1981b0d77e209b56 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-ed0ae1132b37b44c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-request-fo-9ec32231184cff8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/properly-fueling-your-child-for-sports-9a38989fbb516ab5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/client-side-ephemeral-de-identification-of-protected-health-information-phi-in-m-1723769fa40654cb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-ca2-as-a-potential-candidate-gene-involved-in-the-therapeutic-468ef38d57294912 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcome-evaluation-of-percutaneous-coronary-intervention-vs-medical-therapy-alon-8c7ce15ef14f8bd4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-109f27c8ec4ad6fe 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lutetium-177-radiopharmaceuticals-in-cancer-care-progress-and-challenges-d843582ed6f93cf2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-drug-survival-and-treatment-outcome-of-ixekizumab-in-patients-with-sp-277345d1212fc9c3 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-efficacy-and-impact-on-rehospitalization-of-qishen-granules-in-patient-17f7306f6553327e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/case-report-acute-biliary-pancreatitis-after-semaglutide-dose-escalation-in-an-a-a60c1f8f70d97d5a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoparticle-pharmacomicrobiomics-reprogramming-the-microbiome-immune-axis-for-c-19c17144a628d4ac 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-mineral-trioxide-aggregate-diode-and-erbium-chromium-d-65739071b0d85441 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-27d0dea64c7f9ddf 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-pharmacokinetics-pharmacodynamics-and-target-mediated-drug-disposition-mo-ed4b412b6f6c0ff8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/summary-for-patients-tobacco-use-treatment-synopsis-of-the-2026-u-s-department-o-07d3fe471f477728 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hybrid-endoscopic-submucosal-dissection-enhances-efficiency-with-comparable-cura-59f35ebeba6339bc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advances-risks-and-implementation-challenges-of-artificial-intelligence-as-a-for-0aaebc5fc67cb1f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/to-what-extent-is-water-hydration-the-best-method-of-maintaining-voice-protectio-c0b14f3feb98d6fc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/design-and-limitations-of-tumor-microenvironment-responsive-nanocarriers-for-tar-a541e35ac2a228eb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ethical-legal-and-societal-implications-in-xenotransplantation-elsi-a-korean-reg-574b7c8e38dc1ea4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/practicing-in-resource-limited-and-siloed-settings-b8a360d6cc716831 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synbiotic-hqp08-supplementation-for-hair-loss-and-depressive-symptoms-an-open-la-d810c0348c9d2a53 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-participatory-strategies-for-prevention-of-dengue-and-leptospir-8b622e47d75a3a2e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-cardiotoxicity-in-pediatric-patients-with-acute-lymphoblastic-leukemia-and-66bd0483b1ad137d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-tumour-biology-into-surgical-decision-making-for-metastatic-colorect-72069f85a27f2b65 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asparagine-synthetase-deficiency-a-novel-asns-variant-and-a-systematic-review-of-7688496f64879380 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/economic-evaluation-of-primary-health-care-integration-and-targeted-mass-drug-ad-23f6f417faae079e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-following-a-traditional-chinese-medicine-foot-bath-preparation-71dccefa5ac0c66e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-post-procedural-parenteral-anticoagulation-therapy-and-clini-aa105c9902a1b506 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thromboembolic-prophylaxis-in-childhood-idiopathic-nephrotic-syndrome-from-patho-561cd01380060c71 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultrasound-defined-fatty-liver-and-the-risk-of-progression-from-preclinical-to-c-f9a84b6d726a3f6e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hematoma-expansion-in-intracerebral-hemorrhage-neuroimaging-biomarkers-radiomics-e09c758c16081ca4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-non-invasive-brain-stimulation-from-basic-science-to-clinical-applicat-57c6e566091c722c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-fracture-stabilization-to-functional-recovery-a-prospective-clinical-radiol-b0de384d30fed29f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-after-philos-locking-plate-fixa-tion-of-proxi-6cb1d9db4ee8d196 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magnetic-resonance-imaging-evaluation-of-oblique-injuries-introduction-of-the-de-8fc08014efbffe9e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-reproducible-framework-for-auditing-the-trustworthiness-of-clinical-machine-le-e156ce2fb89f21be 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-statistical-similarity-a-clinical-validation-framework-for-synthetic-acut-72e3848e5ab24c81 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-between-clinical-activity-and-inflammatory-response-in-odontogen-bd41993f007c7d9a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-lean-beef-on-resistance-training-induced-strength-and-body-compositio-7dbccd69d52aea28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antioxidant-premedication-reduces-mitochondrial-and-nuclear-dna-damage-repair-in-cecfc8008ef47d6f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ct-derived-myocardial-extracellular-volume-current-evidence-clinical-utility-and-f91615e1f0f6a045 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-phosphate-supplementation-after-newly-detected-hypophosphatemia-in-older-i-5ee50f7a22451580 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-between-social-determinants-of-health-and-clinical-diagnosis-time-o-ba252f64579ea133 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-stroke-crisis-in-ageing-societies-global-trends-risk-factors-and-clinical-va-eebc145ad0ea6bea 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/response-by-maurer-and-fontana-to-letter-regarding-article-coramitug-a-humanized-b092e4d1b40d77b4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-934d9095d9196874 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychological-pathways-from-disease-activity-to-quality-of-life-in-ulcerative-co-0133cc63b78f7bb5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/my-unbearable-wife-gave-me-a-brain-tumor-subjective-theories-of-illness-and-reco-d9c4caf1f4a588e9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-therapists-need-to-be-their-own-clients-the-influence-of-intersectional-pri-12d08479260be075 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/contributions-of-semiotic-cultural-psychology-for-interventions-in-clinical-psyc-cf12230181a710fb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-literacy-antibiotic-use-behaviors-and-awareness-of-antimicrobial-resistan-7a7abb1fc6fe4ec9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-introducing-automated-plan-checking-in-radiation-therapy-effe-220fbd73db8233f8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-effectiveness-safety-and-tolerability-of-ozenoxacin-2-lotion-vs-clind-75efa1fd26813f4c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bacterial-outer-membrane-vesicles-in-colorectal-cancer-interdomain-communication-95e0d6534503eb25 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-early-systolic-blood-pressure-and-clinical-outcomes-in-non-c-69ae09590efea90e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-of-combined-repetitive-transcranial-magnetic-stimulation-and-occupation-b74d503d8324ad1e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacovigilance-practices-educational-interventions-and-barriers-to-reporting-535468794e77582d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occupational-allergies-clinical-presentation-epidemiology-diagnosis-and-preventi-d3e45acd9d403f28 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-conceptual-disease-model-of-atopic-dermatitis-using-data-from-t-b724371d717c237f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anti-tnf-refractory-inflammatory-bowel-disease-associated-with-a-novel-xiap-fram-b48dd066032a9779 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-cuprous-oxide-nanoparticles-green-synthesized-using-artemisia-dracuncu-cc51fb0cd6ece9b8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-evaluation-of-a-hydroxyurea-loaded-invasome-hydrogel-for-enhance-994c6bdc360fa4cc 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photocatalytic-treatment-of-organic-and-pharmaceutical-pollutants-in-wastewater-fb6ba995d39dc801 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tissue-specific-aging-clocks-map-structured-aging-modulatory-drug-score-patterns-9b721b6fd4c871b6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-accuracy-amp-clinical-importance-of-ai-confidence-for-extremity-fract-cf31f9fe3c4a8ca6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/could-previous-appendicectomy-influence-disease-expression-in-axial-spondyloarth-e9e0c066f4387e8f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-performance-of-glass-hybrid-and-short-fiber-reinforced-composite-restor-651b546e41d9bbe2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-interchangeability-of-22c3-and-28-8-pd-l1-assays-for-patient-selection-343e8ac84fe0cb4f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/glaucoma-in-hospitalized-older-adults-polypharmacy-multimorbidity-and-therapy-di-fbced7d96caeaf15 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/specific-treatment-of-attr-cm-in-germany-expert-consensus-of-the-german-society-4b5e24406ecb15a6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-760b3481681182f4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/measuring-what-vlms-don-t-say-validation-metrics-hide-clinical-terminology-erasu-ad6cc70c31430f76 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-blood-biomarkers-after-traumatic-brain-injury-a-subanalysis-of-the-b-62e62e5a6d913481 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07834671-research-on-respiratory-support-decision-making-for-mechanically-ven-18f7097ea8b88c2f 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07833722-management-of-hypokalemia-in-intensive-care-patients-e3b9772dbefc93f6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07833553-comparison-of-efficacy-of-caudal-versus-transforaminal-epidural-ster-ba6604bc010f1f4b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07832422-ischemic-compression-and-low-level-laser-therapy-for-myofascial-low-d513a21624e08e3e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07826013-the-effect-of-horticultural-therapy-on-anxiety-and-quality-of-life-aeeb3468d1ba64e9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07783802-a-study-of-clazakizumab-ly5724886-in-adults-with-elevated-hscrp-and-29441caf9fd10fa6 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07775313-base-edited-hematopoietic-stem-progenitor-cell-gene-therapy-for-trea-598ef3dcb0ccb96b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07767487-a-study-of-ly4226695-in-healthy-participants-5cb65fa6ef63d898 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07737756-a-real-world-medical-chart-review-of-spinal-muscular-atrophy-patient-67bc8c57e8f46d84 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07507760-oral-decitabine-plus-ivosidenib-as-first-line-for-older-unfit-adult-72d54845c186722b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07504601-investigating-the-analgesic-potential-of-2r-6r-hnk-in-acute-pain-in-7d802ea0b5cc5a4e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07488676-a-study-of-asp546c-in-adults-with-gastroesophageal-cancer-pancreatic-8d01bc3f698a8cf8 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07437976-a-natural-history-of-genetic-and-environmental-predictors-of-puberta-6b2ccb1e0c1c166d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07409272-a-study-to-evaluate-the-effectiveness-and-safety-of-setidegrasib-giv-09ad5ffe87abbd3b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07222709-a-study-to-assess-the-adverse-events-and-how-oral-abbv-1042-moves-th-19ae8bf9c118cc7b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07222189-a-study-to-investigate-the-long-term-safety-tolerability-and-efficac-4c589d37fe3b3d76 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07053423-a-study-to-investigate-airway-inflammation-with-dupilumab-subcutaneo-f76e86c6aa568fa4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06875310-a-study-of-adagrasib-plus-pembrolizumab-plus-chemotherapy-vs-placebo-b1d1bb9e85e90d8c 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06833944-high-intensity-interval-training-in-the-treatment-of-familial-hyperc-1b8bcbea5515768a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06828042-safety-and-efficacy-of-universal-cd19-targeting-car-t-cells-in-refra-46bf8248aff6d69d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06641908-anti-gd2-adc-m3554-in-advanced-solid-tumors-333d9dc4d4693020 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06585787-a-study-to-evaluate-karxt-as-a-treatment-for-psychosis-associated-wi-68a1e1572e63aeec 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06453044-mosunetuzumab-and-polatuzumab-vedotin-for-the-treatment-of-patients-f92dc5572b576547 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06393452-safety-pharmacokinetics-and-efficacy-of-pp405-in-adults-with-aga-cf7ba5e394b1e7a5 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06281665-treatment-with-aspirin-after-preeclampsia-tap-trial-d452b736868de309 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06226883-a-phase-2-study-to-evaluate-morf-057-in-adults-with-moderately-to-se-5f3287f5b75539d0 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06128551-study-of-elironrasib-and-daraxonrasib-as-monotherapies-and-combinati-018bc1740e4ec72a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06109272-a-study-to-assess-the-dose-adverse-events-and-change-in-disease-acti-3cbaca2f6fede566 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06081894-a-trial-to-evaluate-the-efficacy-and-safety-of-aficamten-compared-to-3f0db88811c38c18 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05825274-tdcs-to-treat-drug-resistant-epilepsy-75be45242a7ab4de 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cb 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05419024-imaging-and-biopsy-of-people-with-hiv-1-undergoing-analytic-treatmen-ba9c2ed4984d9b75 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05201066-roll-over-study-for-patients-who-have-completed-a-prior-novartis-spo-f4d66c80a684873d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04928846-a-study-to-assess-disease-activity-and-adverse-events-of-intravenous-aad3d7c2569dbe63 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04925479-study-to-determine-the-dose-and-safety-of-asciminib-in-pediatric-pat-36818f90875f077b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04639830-electrophysiologic-sleep-phenotyping-and-sleep-dependent-neuro-matur-f66afd5ddf8abb8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04384367-efficacy-and-safety-of-rizatriptan-naproxen-10-550-mg-in-the-acute-t-b4d7fed8ac67cb46 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04269902-testing-early-treatment-for-patients-with-high-risk-chronic-lymphocy-cf81092206932f4e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03766009-increasing-patients-engagement-in-breast-cancer-surgery-decision-mak-9cb70c96b7ebe325 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03602599-chronic-graft-versus-host-disease-in-the-oral-cavity-of-patients-fol-917cfe1b45e00a8d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03459287-study-to-evaluate-the-efficacy-safety-of-the-intercept-blood-system-27fa67412869567a 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03253705-samples-from-human-subjects-to-facilitate-basic-translational-and-cl-dd8e4dde62e55019 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02262832-compassionate-use-of-metreleptin-in-previously-treated-people-with-g-b70e5c26c71574b9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02116764-analysis-of-patients-treated-for-chronic-granulomatous-disease-since-9b8692f247eb9b9b 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01925196-natural-history-and-biomarkers-of-amyotrophic-lateral-sclerosis-and-85158fa590642c6d 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01857934-therapy-for-children-with-advanced-stage-neuroblastoma-4a846ae16a327054 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01247597-dicer1-related-pleuropulmonary-blastoma-cancer-predisposition-syndro-483746454e3e0819 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00092222-virotherapy-and-natural-history-study-of-khsv-associated-multricentr-0a1ef180e9bc1d96 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00043472-removal-of-the-ovaries-fallopian-tubes-and-ca-125-screening-to-reduc-03a60ad923366b92 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00034424-cause-of-familial-testicular-cancer-b37185d4ec3be3ca 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00024622-pet-scanning-in-parkinson-s-disease-db6af6973e31a489 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00023049-genetic-analysis-of-hereditary-disorders-of-hearing-and-balance-65bd947aa9000148 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00004847-diagnosis-of-pheochromocytoma-05c9db90843e0e42 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001846-collection-and-distribution-of-blood-components-from-healthy-donors-2ef5bdb84e8cdf6e 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001595-an-investigation-of-pituitary-tumors-and-related-hypothalmic-disorde-44f1228058efa690 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001254-evaluating-pancreatic-tumors-in-patients-with-zollinger-ellison-synd-c749f4fce25c54a9 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sputum-based-test-may-identify-drug-targets-in-asthma-and-copd-patient-care-onli-9b7f052101582566 2026-09-22T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amcham-imss-deal-pledges-us-44-million-to-bring-clinical-trials-to-mexican-publi-052095dbcfb7da9a 2026-09-21T23:39:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nice-recommends-enhertu-for-her2-low-advanced-breast-cancer-in-england-9d334852ef112a45 2026-09-21T22:50:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/drummond-warns-rubio-of-national-security-risk-in-pharmaceutical-supply-chain-5a65cb2ace796337 2026-09-21T22:48:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-recalls-and-warnings-third-glutathione-recall-issued-over-endotoxin-contamin-07b548b075a272fe 2026-09-21T22:39:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-rulemaking-chatter-lifts-hong-kong-s-china-biotech-names-4fcfe264207382d9 2026-09-21T22:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-6bcac29ff06fe76b 2026-09-21T21:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-logistics-market-to-reach-usd-194-0-billion-by-2034-at-7-7-cagr-d-405b29a18e79aec5 2026-09-21T21:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-and-leveraged-etfs-lead-market-d-9c02833c76771b58 2026-09-21T21:28:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-plant-078eb0965183eec9 2026-09-21T21:21:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/dompe-settlement-highlights-doj-continued-scrutiny-of-pharmaceutical-manufacture-433de672942d089b 2026-09-21T21:15:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/iam-ipo-news-small-molecule-biotech-iambic-therapeutics-files-for-a-100-million-3bc12612e27dfbee 2026-09-21T21:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-pharmaceutical-factory-in-houston-2f381a479b3555a2 2026-09-21T20:58:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/screening-china-origin-biotech-ip-a-new-u-s-eu-divide-fe79769761ea8dd8 2026-09-21T20:45:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-4b5e30b480cbde92 2026-09-21T20:38:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicus-pfizer-deal-was-not-a-fire-sale-a-strategic-bet-on-de-risked-adc-drug-8e03cd57f1797c93 2026-09-21T20:35:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/buerger-s-disease-clinical-trial-pipeline-gains-momentum-3-91e1bc0bbb6b2bea 2026-09-21T20:24:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-glp-1-shortage-is-over-mass-market-compounding-should-be-too-5d8cd6869a85189b 2026-09-21T20:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-connected-peninsula-company-plots-ipo-as-it-takes-on-eczema-and-more-0871b8e09373ffce 2026-09-21T19:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/par-health-issues-voluntary-nationwide-recall-of-two-lots-of-dexmedetomidine-hcl-488b45799ea71d6a 2026-09-21T19:37:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/positive-topline-phase-3-study-results-lumateperone-for-manic-episodes-in-bipola-ea5127591948df34 2026-09-21T19:34:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-why-is-it-back-in-the-spotlight-feca7b108b11fdaf 2026-09-21T19:11:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-milan-leadership-summit-returns-with-supply-chain-focus-543b72ef7ec0a6e6 2026-09-21T19:06:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-how-the-generous-model-applies-mfn-pricing-to-medicaid-3108639fbd284b85 2026-09-21T19:04:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-analyses-of-hlp003-for-the-adjunctive-treatment-of-mdd-610c32551287df6e 2026-09-21T19:04:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-61a649d42d701917 2026-09-21T19:00:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-forms-ai-powered-drug-discovery-partnership-with-iambic-pharmexec-7df1eac9f5ddbb27 2026-09-21T18:57:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-expand-alternatives-to-animal-testing-in-drug-develop-0ab1dcb84feb442a 2026-09-21T18:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/s2s-china-selects-10-biotech-finalists-to-pitch-global-investors-at-westlake-uni-cc798694b80a8b1b 2026-09-21T18:33:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/sec-fda-information-sharing-mou-implications-for-pharma-and-biotech-f12ad8cd85d5f095 2026-09-21T18:24:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l608-wins-fda-approval-for-phase-2-trial-shares-623a9af03fd0b72d 2026-09-21T18:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/life-sciences-real-estate-trends-what-to-expect-3bd7b4d3a44b9c76 2026-09-21T18:05:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-21T17:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing-2a5644680d80e2c1 2026-09-21T17:14:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugs-racket-kingpin-s-pharmacy-stayed-open-after-raid-health-officer-suspended-710aba0a714d4a51 2026-09-21T17:14:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspension-case-k-taka-health-dept-warns-consumers-over-54ab0d264ee858a9 2026-09-21T17:13:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-developer-adarx-seeks-1-74-billion-valuation-in-us-ipo-da6c89fec62607a7 2026-09-21T16:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-21T16:20:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenetic-to-acquire-santersus-in-net-targeting-biotech-combination-ec88c0dae17857a4 2026-09-21T16:15:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-etfs-to-buy-as-cancer-drug-breakthroughs-accelerate-bd41f997cae1257c 2026-09-21T16:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bengaluru-assistant-drug-controller-suspended-in-counterfeit-drug-case-3638b689e7e0c3d9 2026-09-21T15:50:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-commission-approves-roche-s-susvimo-for-the-treatment-of-neovascular-ag-5503298c000d9a8a 2026-09-21T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-surges-9-as-phase-3-melanoma-data-wins-presidential-symposium-slot-merck-3da8f65777798006 2026-09-21T15:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-of-my-top-small-cap-biotech-picks-made-a-move-here-s-how-i-trade-it-6eb55c5568c32d22 2026-09-21T15:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bmy-vs-gild-which-biotech-stock-looks-more-attractive-now-6c620882c75be90d 2026-09-21T15:08:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-top-7-atypical-psychedelics-a-brief-clinical-guide-3d93abb04fc90f32 2026-09-21T15:06:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-roundup-on-the-cannabis-sector-psychedelic-sector-a4229cf49083a849 2026-09-21T15:01:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/bytedance-baidu-hengrui-novo-nordisk-driving-breakthroughs-in-ai-pharmaceutical-fbcbc6c19d988c7c 2026-09-21T15:01:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-and-biotech-industry-audit-services-for-gmp-gxp-and-supplier-compliance-2ecc2a1cefcf64f8 2026-09-21T14:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-wants-pro-life-states-to-keep-waiting-b6f6153c4948a5f2 2026-09-21T14:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cspc-pharmaceutical-group-sehk-1093-expands-its-pipeline-is-the-stock-still-unde-873fbda566f6532f 2026-09-21T14:52:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-and-clinical-site-readiness-to-initiate-p-2dfc2ee296889841 2026-09-21T14:45:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/plug-and-play-seattle-picks-11-startups-for-4th-cohort-from-space-robotics-to-bi-a4ef32ff512f3201 2026-09-21T14:42:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/beijing-unveils-blueprint-for-biomedical-dominance-by-2030-d2e6d08e6ff0538c 2026-09-21T14:41:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/concord-biotech-bonus-issue-sparks-rally-pharma-stock-jumps-6-on-maiden-share-re-3ca3b429b4874d3e 2026-09-21T14:28:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/evita-clinical-trial-evaluates-oral-vitamin-c-for-pre-cancerous-blood-disorders-8e446074c31c386e 2026-09-21T14:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-ac0ba1a6f705851f 2026-09-21T13:59:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-alternatives-to-animal-testing-efae5931c8e859cd 2026-09-21T13:45:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-septiembre-de-2026-224e8a08e13866ca 2026-09-21T13:44:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cancels-16-drug-licences-suspended-08-others-in-connection-with-alleged-dist-51785b064dcf2ded 2026-09-21T13:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-pharma-reform-strategic-implications-for-us-drugmakers-8f7f8ee4ad186bb7 2026-09-21T13:27:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-targets-25-share-of-global-first-in-class-drugs-in-new-5-year-plan-0e7df4b725539007 2026-09-21T13:12:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-stock-price-expected-to-rise-barclays-anal-81130dfa0ccc6837 2026-09-21T13:05:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7 2026-09-21T13:00:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-new-cholesterol-drugs-get-their-first-global-approval-in-europe-61a68e250907fc8e 2026-09-21T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-opens-expedited-drug-trial-pilot-to-cut-development-delays-f3806e23c82077de 2026-09-21T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dc 2026-09-21T12:59:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/telix-tlx-lines-up-us-1-65b-cancer-drug-merger-and-a-big-revenue-jump-8adff125aee08116 2026-09-21T12:56:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-sets-terms-for-350-million-ipo-7c6df0ecf3d07353 2026-09-21T12:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-inc-bofa-global-research-raises-price-objective-to-400-from-392-76033b6bd017aee9 2026-09-21T12:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-china-biotech-licensing-expected-to-thrive-as-washington-softens-stance-news-7bfa8d1d5a5b74b0 2026-09-21T12:40:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-adjusts-price-target-on-krystal-biotech-to-400-from-392-keeps-buy-rating-3e1641c6da3c6b68 2026-09-21T12:34:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/factbox-weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competiti-5514ab11a1196d72 2026-09-21T12:28:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/rhelion-subsidiary-supplies-psilocybin-for-phase-3-palliative-care-trial-0d4d220a9ee9c49e 2026-09-21T12:11:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/denmark-eyes-shortage-substitution-protocols-as-industry-urges-tight-limits-d1dc310ade3ee8de 2026-09-21T12:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92 2026-09-21T12:10:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/arch-biopartners-under-pressure-clinical-stage-biotech-faces-renewed-selling-as-327b8f6542f8321e 2026-09-21T12:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-targets-25-of-global-first-in-class-drugs-by-2030-in-new-pharma-five-year-f8d103925f821267 2026-09-21T12:06:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-2-trial-suggests-vitamin-c-may-benefit-people-with-pre-cancer-blood-disord-64b38f62af9ca22e 2026-09-21T12:05:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/filament-ships-psilocybin-drug-pex010-for-phase-3-trial-on-psychological-distres-00504eb35086a553 2026-09-21T12:03:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competition-heats-54efba15b344cc0f 2026-09-21T12:01:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspended-as-karnataka-probes-fake-drug-racket-eb671632b4449c57 2026-09-21T12:01:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/imaavy-affected-lots-may-contain-glass-particles-9a9a8e6dd55fc1e3 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-14963d1b5f3d3bc5 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-s-drug-price-plan-targets-foreign-freeloaders-but-shoots-american-innovato-5e14093c8aaa4a87 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-6b060a185e233d47 2026-09-21T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rhelion-life-sciences-wholly-owned-subsidiary-filament-health-delivers-pex010-to-2398f0f9f087f4a7 2026-09-21T11:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/psilocybin-doses-without-hallucinations-will-be-tested-in-end-of-life-care-6c1213d2afac37ae 2026-09-21T11:49:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/virtual-biotech-employs-37-000-ai-agents-for-end-to-end-drug-development-8f7d97a93a576cdc 2026-09-21T11:46:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyllene-appoints-seasoned-biotech-exec-as-cfo-74f91b753010fd2c 2026-09-21T11:40:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-exports-continue-to-strengthen-the-swedish-economy-6d1e9ae333cb8b5f 2026-09-21T11:37:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-ema-y-hma-abren-el-proceso-de-comentarios-sobre-la-nueva-guia-de-eu-in-para-i-b9a7929b040a0936 2026-09-21T11:26:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-minister-says-pfizer-c-f-agency-failed-to-aid-fake-drug-probe-d544ad166f836728 2026-09-21T11:23:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-community-based-scale-up-of-integrated-community-health-worker-le-05286051f35c02ca 2026-09-21T11:22:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-microwave-photonics-platform-for-cancer-detection-and-treatment-4e2c58f5b234309a 2026-09-21T11:22:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-the-interaction-between-chronic-pain-and-genetics-in-contributing-5d67fb178fa044ee 2026-09-21T11:22:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-towards-predictive-computational-platform-for-drug-solubilization-1268e26242a4e7b4 2026-09-21T11:22:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-controlling-reactive-species-delivery-in-cold-plasma-jets-a-key-c-7546c6a43992920d 2026-09-21T11:22:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-electrochemical-carboxylic-acid-exchange-for-sustainable-drug-dev-e80014a705f27d3b 2026-09-21T11:22:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/brazil-pharmaceutical-distributors-face-mounting-financial-pressure-2eeef9a7b9aca460 2026-09-21T11:20:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/sichuan-biokin-pharmaceutical-s-unit-receives-milestone-payment-from-bristol-mye-ca99112d5b22276b 2026-09-21T11:16:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/psychedelics-are-wall-street-s-next-trip-why-this-biotech-stock-is-already-up-20-52049d1cb6186539 2026-09-21T11:08:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial-7d805f10ecf38946 2026-09-21T11:03:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-4e3af3cef35b6b21 2026-09-21T11:02:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-993c912068e3ffbe 2026-09-21T11:02:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/tiziana-announces-last-patient-completes-last-visit-in-phase-2a-inform-ms-trial-121aeb1f6cd0e04c 2026-09-21T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alkermes-announces-positive-phase-1b-results-demonstrating-clinical-proof-of-con-e143bd6657dbae3b 2026-09-21T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-inline-refractive-index-monitoring-can-improve-real-time-peptide-manufacturi-6daaaf2be2a7405b 2026-09-21T10:54:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/singapore-draws-international-biotech-vcs-as-asia-pacific-life-sciences-sector-t-8b267d226e97ee94 2026-09-21T10:53:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-co-ltd-to-go-ex-dividend-on-september-22nd-2026-with-7e95578a30c6b612 2026-09-21T10:48:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-s-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-approved-i-cb6eee590ac0416c 2026-09-21T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-nyse-teva-legal-chief-files-273k-share-sale-notice-e62f1c4bffd47859 2026-09-21T10:40:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/tekpac-s-intelligent-packaging-increases-output-for-patch-manufacturer-5fc87af611260110 2026-09-21T10:30:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-has-approved-29-u-k-led-cancer-drugs-since-2021-now-a-u-k-regulator-will-a64efa1f5f19d8b7 2026-09-21T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/os-therapies-completes-fda-type-c-statistical-methods-meeting-and-provides-updat-79fead0c1f7c2adf 2026-09-21T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-secures-full-fda-nod-for-inluriyo-verzenio-breast-cancer-combo-986279ff4c2ee3b2 2026-09-21T10:29:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-buys-three-non-incretin-obesity-programs-from-kallyope-1771b5edb75f4697 2026-09-21T10:29:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-aug-16bd5e27d65a23b1 2026-09-21T10:28:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-2a4014b9e82727c7 2026-09-21T10:28:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-reform-of-eu-drug-regulations-what-will-change-for-patients-1b494b7bc3bbb314 2026-09-21T10:25:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/metavallon-backs-parkinson-s-biotech-anacalypsis-in-first-of-its-kind-greek-deal-a0596c80e643d916 2026-09-21T10:14:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-collaboration-to-advance-a-novel-therapy-for-alzheimer-s-disease-f02f2d6a6aefabfc 2026-09-21T10:09:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-pfizer-depot-7-other-firms-face-licence-suspens-3be6e17a0c46130a 2026-09-21T10:09:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-treasury-reportedly-drafting-rules-to-preserve-pharma-licensing-deals-with-ch-267bf55a61b7fc6a 2026-09-21T10:06:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3 2026-09-21T10:03:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannabinoids-vs-opioids-is-chronic-pain-treatment-at-a-turning-point-6360efc5a5b20214 2026-09-21T10:00:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-tide-of-china-biotech-deals-seen-as-us-curb-fears-fade-analysts-aaba7a319c133b2c 2026-09-21T10:00:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-finance-report-england-2025-to-2026-edfdf55f46596236 2026-09-21T09:52:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-activity-report-england-2025-to-2026-d04cfc1369caa66d 2026-09-21T09:52:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35 2026-09-21T09:51:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-october-2026-673a62d4be0d46e6 2026-09-21T09:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-43-report-data-to-week-42-data-up-t-d32e68d6017bb7c3 2026-09-21T09:51:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2025-to-2026-625b82782f2a1916 2026-09-21T09:51:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-39-report-data-to-week-38-data-up-t-b701a0f0114ed05c 2026-09-21T09:50:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/d-d-pharmatech-s-head-of-r-d-park-eun-ji-newco-bridges-early-stage-biotech-firms-b72d729bb82a03d9 2026-09-21T09:45:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/belgium-s-novadip-biosciences-raises-10-4-million-to-fund-pivotal-clinical-trial-1c00f7f63d3d96ab 2026-09-21T09:40:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/thousands-invited-to-register-for-public-panel-for-independent-commission-on-adu-52b360f1b8267410 2026-09-21T09:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/3-chinese-biopharma-stocks-retail-investors-are-watching-for-licensing-deals-f9c5948024fb39f8 2026-09-21T09:24:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-inc-nasdaq-rare-is-in-focus-now-2794a473faf0e70f 2026-09-21T09:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sarepta-therapeutics-srpt-stock-analysis-navigating-the-biotech-waters-with-a-fo-00f2039c62c0d646 2026-09-21T09:22:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/legend-biotech-corporation-legn-stock-analysis-unveiling-a-175-potential-upside-bcd9d089c6ca5a63 2026-09-21T09:22:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-inc-krys-stock-analysis-a-look-at-its-14-36-potential-upside-9a61874672731d38 2026-09-21T09:21:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/exelixis-inc-exel-stock-analysis-navigating-biotech-with-strong-revenue-growth-a-5788861c9117fa48 2026-09-21T09:21:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuvalent-inc-nuvl-stock-analysis-navigating-the-biotech-landscape-with-a-clinica-7e778788f7bae560 2026-09-21T09:20:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-130dcd4d2d8d5288 2026-09-21T09:19:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-enhanced-surveillance-form-969ec8a257418767 2026-09-21T09:15:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-pharmaceuticals-vrtx-stock-analysis-a-biotech-powerhouse-with-11-97-poten-386828f0479eef3f 2026-09-21T09:15:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66f 2026-09-21T09:14:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-commercial-opportunities-9e4f936a0befa657 2026-09-21T09:09:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-suspends-pfizer-c-f-depot-licence-in-fake-drug-case-warns-consumers-ov-61ae4f712869af8f 2026-09-21T08:58:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewon-pharmaceutical-brings-shinbaro-in-house-to-expand-south-korea-osteoarthri-06deb3f19266a298 2026-09-21T08:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cue-chalks-up-phase-2-hives-win-for-xolair-challenger-dca24fea5b2e4874 2026-09-21T08:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-spurious-drugs-racket-fda-cancels-16-drug-licences-suspends-pfizer-c-f-583b24989cc671ce 2026-09-21T08:49:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-and-lilly-backed-trex-bio-both-set-out-plans-to-join-biotech-ipo-stamp-d978dc40cc95aef6 2026-09-21T08:29:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/bofa-securities-lifts-sino-biopharmaceutical-target-to-hk-7-3-bullish-on-chinese-b25213c517e317db 2026-09-21T08:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nykredit-a-s-takes-position-in-teva-pharmaceutical-industries-ltd-teva-8ef68b53d2f7b566 2026-09-21T08:12:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/anthropic-bytedance-enter-ai-drug-discovery-the-next-coding-faces-critical-data-949e67c2cfec7bcb 2026-09-21T08:10:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/aspen-achieves-top-10-ranking-for-integrated-reporting-excellence-11891286e263540b 2026-09-21T08:04:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/buy-sun-pharmaceutical-industries-target-of-rs-2070-geojit-financial-services-05d4bece45133dba 2026-09-21T08:01:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-may-202-2cc50be828051e6c 2026-09-21T07:54:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-39-report-data-to-week-38-dat-1bbeb1fdd2fcb78d 2026-09-21T07:43:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/aston-university-joins-forces-with-biotech-firm-to-develop-realistic-human-skin-5439803eb98b58fb 2026-09-21T07:39:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korea-s-inventera-reports-phase-3-success-for-mri-contrast-agent-plans-reg-7e38950a6ba7475b 2026-09-21T07:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antengene-starts-phase-iii-clinch-3-trial-of-atg-022-in-advanced-gastric-cancer-02e84e96f3c002c3 2026-09-21T07:33:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-plans-more-support-for-pharma-innovation-f77ec0948695270f 2026-09-21T07:09:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventera-s-mri-contrast-agent-passes-phase-3-trial-in-korea-22fdf31a869b455e 2026-09-21T06:53:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/interview-mash-moves-beyond-clinical-graveyard-as-focus-shifts-to-targets-biomar-778863fe92e5aac3 2026-09-21T06:49:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/lavengratinib-shows-100-response-rate-in-lowest-dose-achondroplasia-cohort-c1eaa9b89bb2e951 2026-09-21T06:38:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-b2b1f4cf310740f2 2026-09-21T06:31:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/neurotech-international-initiates-phase-3-beyond-harmony-trial-with-first-patien-bc6f61556b31fc81 2026-09-21T06:20:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-aspen-betting-on-the-right-hiv-prevention-product-14903d010e56bd11 2026-09-21T06:19:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/copenhagen-biotech-takes-first-step-toward-european-approval-eyes-major-reformul-88ce2eac112529e9 2026-09-21T06:14:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspension-case-k-taka-health-dept-warns-consumers-over-62b3da0dab88be39 2026-09-21T06:13:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/beacon-lights-path-to-fda-approval-with-pivotal-trial-win-for-rare-vision-loss-g-de3d6ab41f73e76c 2026-09-21T05:57:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/cicc-cuts-alibaba-health-target-price-to-hk-4-5-bullish-on-pharmaceutical-busine-2ef4c2c59948d673 2026-09-21T05:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sunshine-guojian-pharmaceutical-co-ltd-xssc-688336-added-to-ftse-all-world-index-f7d596060f75cd57 2026-09-21T05:21:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-joins-hands-with-bondwell-for-protein-production-82d9ae6b6395045f 2026-09-21T05:10:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-eyes-q4-phase-3-data-for-depression-drug-hlp003-fe46f092d7c7b986 2026-09-21T05:02:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/cybin-eyes-q4-phase-3-data-for-depression-drug-hlp003-0c74433ec5a2cf09 2026-09-21T05:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aluminum-pvc-blister-film-market-forecast-to-2035-pharmaceutical-demand-drives-5-953d6d97f21cf2cb 2026-09-21T05:01:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-week-ahead-xlv-beats-the-market-here-are-the-stocks-readouts-and-events-8162588003ba2afa 2026-09-21T04:37:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/north-china-pharmaceutical-company-ltd-xssc-600812-dropped-from-ftse-all-world-i-b96971880c9cd718 2026-09-21T04:35:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/heilongjiang-zbd-pharmaceutical-co-ltd-xssc-603567-dropped-from-ftse-all-world-i-4353837e375a403a 2026-09-21T04:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-phase-iii-diabetes-trial-start-require-action-from-uni-bio-science-shares-033cbff8c0320fac 2026-09-21T04:28:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/sansure-biotech-inc-xssc-688289-dropped-from-ftse-all-world-index-58517ea7bc89902e 2026-09-21T04:27:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-deals-a80913ab3deb4527 2026-09-21T04:20:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-resources-boya-bio-pharmaceutical-group-co-ltd-xsec-300294-dropped-from-ft-b7061d9fea7cd209 2026-09-21T04:11:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-warns-texas-beverage-companies-about-acidified-food-unapproved-drug-claims-5909ec9e189f3706 2026-09-21T04:02:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/ventilator-recall-coopersurgical-removes-inca-infant-nasal-cpap-sets-f3698262eaa2b3c4 2026-09-21T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/convenience-kit-correction-avid-medical-issues-correction-for-kits-containing-hu-1b4aecd26284ce1a 2026-09-21T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-pfizer-labels-expired-vials-seized-karnataka-fda-cancels-16-licences-suspen-94d0597343aefd1e 2026-09-21T03:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-to-expand-into-protein-process-development-with-us-bondwell-999cb539da410bad 2026-09-21T03:26:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/celltrion-wins-ema-approval-to-modify-phase-3-trial-for-darzalex-biosimilar-ct-p-b83c8c64d39982d8 2026-09-21T03:25:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/shenqi-pharmaceutical-share-price-skyrockets-160-the-stock-is-truly-magical-2c0bba098ab6dc55 2026-09-21T03:14:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/nyrada-raises-fresh-capital-to-fund-xolatryp-phase-iia-and-pipeline-expansion-4c148b1b6b22f576 2026-09-21T03:10:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/kolon-tissuegene-ceo-noh-moon-jong-steps-down-after-tg-c-phase-3-failure-93ba35e01c4a0a62 2026-09-21T02:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-suspends-8-drug-licences-in-counterfeit-medicine-crackd-f0e2dfff72f4bb07 2026-09-21T02:27:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-uncovers-farmhouse-drug-scam-with-fake-pfizer-labels-fa113abe91479c41 2026-09-21T02:12:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/abl-bio-s-credibility-in-doubt-as-market-cap-drops-by-10-trillion-won-in-eight-m-6125fa47849c124e 2026-09-21T01:56:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/cha-biotech-s-us-unit-matica-expands-beyond-cgt-into-protein-cdmo-3e1fa8b19d2893e9 2026-09-21T01:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kolon-tissuegene-shifts-to-sole-leadership-as-no-resigns-after-tg-c-setback-chos-78b39badd6d85917 2026-09-21T01:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-drug-licences-after-rs-5-05-crore-spurious-medicine-rac-71f3f5a689bc8cb1 2026-09-21T01:25:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-says-hs-10374-meets-co-primary-endpoints-in-phase-iii-plaq-c406088c5e696e9d 2026-09-21T01:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-anti-aging-to-biotech-taiwan-looks-to-take-its-exosomes-global-8b1cffaebe2d4f7a 2026-09-21T01:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antengene-announces-first-patient-dosed-in-pivotal-phase-iii-clinch-3-study-of-a-46d88b9387463d03 2026-09-21T00:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-pivotal-phase-3-clinical-trial-of-hs-1037-5e494e720e07789d 2026-09-21T00:24:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/nephrotic-syndrome-clinical-trial-pipeline-gains-momentum-3-3dcb122cc4863365 2026-09-21T00:24:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-20d1e45ad8f41ec4 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-97a3580102cfaf35 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-f7733853b6214ae0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tem-11a455d22d2f487e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-sta-3764daf81725a8e8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pri-46565154b7c80bf6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-pro-a46738e923f10604 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-intermediaries-and-approaches-to-strengthen-public-health-data-exchange-4fc8495db52da975 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/request-for-information-on-electromagnetic-fields-emfs-radiofrequency-rf-radiati-adf4d970aa383e2a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/solicitation-of-nominations-for-membership-on-the-national-vaccine-advisory-comm-7829fc374a16ba21 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-evalu-34665635a9d20190 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-state-offices-of-rural-health-coordination-and-de-f3a019ef42d0893b 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/esther-villanueva-valdes-m-d-decision-and-order-6920fac42a4abfcb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i-0219f45fb611f4fb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/john-ramsay-walters-m-d-decision-and-order-508288de44a083a6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-2cd2bb9dfe90d36a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-90b2d8c9d1af74ac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-quality-improvement-technical-assistance-pr-9960416381329507 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-children-s-expands-newborn-screening-to-identify-virus-that-can-5be78e10f5542c12 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-shower-habits-for-healthy-skin-17d870af5aaadff9 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-regulatory-acceptability-of-hierarchical-composite-endpoints-in-inf-8fdddd6693552588 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preclinical-and-first-in-human-phase-i-trial-of-mt200605-a-novel-trkb-agonist-fo-1829f78db2d42e94 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetics-and-safety-of-a-modified-release-psilocybin-formulation-a-sad-p-b737575b41477429 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supporting-the-primary-outcomes-of-the-mirai-trial-for-the-adjunctive-digital-th-24ef5a380338f8fe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cost-effectiveness-and-value-implications-of-veligrotug-versus-teprotumumab-for-7ece3f4eda8bff11 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-free-remission-in-early-peripheral-spondyloarthritis-including-psoriatic-ar-0aa0a17d1dd07f91 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-pharmacist-led-medication-review-on-drug-related-problems-among-outpat-d98465ff90ef3962 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-orthodontic-management-of-impacted-teeth-associated-with-retained-p-4cc1e189c772934d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/contemporary-classifications-of-alzheimer-s-disease-a-critical-review-of-clinica-881e2ebbb9a0f093 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-effects-of-myofascial-release-and-bowen-therapy-in-patients-with-tex-0ca1011620b24697 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/redefining-post-xenotransplantation-surveillance-leveraging-metagenomic-next-gen-b5529587c7664a12 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-answers-to-agents-what-must-change-before-generative-and-agentic-ai-become-29d767d349ffc4c0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-dose-escalation-trial-of-psilocybin-assisted-therapy-for-bipolar-i-d6af23c5c79be8b0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanotechnology-for-drug-delivery-systems-in-colorectal-cancer-recent-development-407dba257167da55 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-artificial-intelligence-in-hepatology-when-deep-learning-me-a568d88464097fac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyethylene-glycol-based-bowel-preparation-and-gut-dysbiosis-clinical-implicati-0b34416aee8a965b 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/b3c94bebd28f7b8a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-dispensary-pharmacists-perspectives-on-the-responsible-implementation-cfbe71d78e165236 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerated-wound-healing-with-a-bilayer-biodegradable-synthetic-matrix-in-post-ef236746b1d49e2c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-longitudinal-analysis-of-the-clinical-practice-of-ketamine-assisted-psychother-6ab9b95624cbf138 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/precision-cut-tumor-slices-a-biomimetic-tool-for-accelerating-oncological-develo-7226c7cb1b69ee04 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-a-large-language-model-chatgpt-5-for-detecting-potential-drug-drug-in-816f2974050e0720 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/explainable-ai-based-prognostication-of-patients-with-resectable-colorectal-live-2fbabdacdf9df95d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-individualized-surgical-pathways-in-elderly-patients-with-s-8be373a0ada7c9ac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cholesterol-in-hematological-malignancies-metabolism-mechanisms-and-clinical-imp-9a30fa29c2722f2e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/radiomics-and-deep-learning-for-immune-checkpoint-inhibitor-outcomes-imaging-der-c24c9e0431952223 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-hypertension-and-endocrine-pathways-molecular-and-clinical-perspective-f45527b617e638a0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-metabolic-indices-with-in-stent-restenosis-and-its-angiographic-s-e1466792d8c505f7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-for-alcohol-opioid-and-cannabis-use-disorders-screening-af0d522dc83a2f40 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-endovascular-stenting-versus-bypass-surgery-for-aortoiliac-c8a13ad848e43792 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/experimental-data-analysis-and-improved-cytochrome-p450-site-of-metabolism-predi-c9f109a994421cca 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correlation-of-hematological-parameters-with-serum-ferritin-in-pregnant-women-fr-c9a73dba51df0812 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/semaglutide-effects-on-insulin-sensitivity-and-cell-function-in-patients-with-sc-75140098b7871905 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/myopia-control-effect-of-continuous-versus-sinusoidal-photobiomodulation-therapy-56eab16e14bc0b7e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-system-for-independent-evaluation-of-clinical-prediction-models-while-preservi-8fb78fb786fc2a3e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clostridium-ramosum-bacteremia-clinical-significance-and-outcomes-in-a-multicent-aed8148e87cde446 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-surgical-management-of-humeral-fractures-in-dogs-630477cc2610da7a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-prediction-with-time-varying-predictors-in-pediatric-hospital-medicine-e1b6797d232c89eb 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/72120-role-of-cross-coupling-reactions-in-drug-discovery-and-development-c3d94fd4f2f85350 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-clinical-and-laboratory-findings-associated-with-mortality-during-continuo-9407e7b095fca8cf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-trial-of-burr-hole-surgery-with-or-without-irrigation-for-chronic-sub-1a791efcaca9175c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mir-107-serves-as-a-clinical-biomarker-for-acute-pancreatitis-and-promotes-infla-184ec7a1bcd62e51 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-age-and-outcomes-of-evidence-based-feeding-protocol-versus-u-55c081db85ef4e3d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-the-unified-treatment-for-emotion-regulation-an-95ba566aa1d0d048 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-environmental-burden-of-the-neuro-conda-trial-b843a9e61763332f 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-liberations-two-physiological-targets-implications-of-the-x-copd-trial-d4756dae96dd95bf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-genetic-spectrum-of-dual-rare-genetic-diseases-revealed-by-whole-ex-c11cb01b29dfbeac 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-the-effectiveness-of-sexual-education-lactofem-probiotic-supplementati-6de2093c73f923ae 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-tricalcium-phosphate-grafting-on-implant-stability-and-peri-implant-ra-6c4647c34f739ce5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-clinical-outcomes-and-learning-curve-study-of-robot-assisted-precision-ost-e633bc562db9c390 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reproductive-health-factors-associated-with-clinical-breast-examination-uptake-a-1fb1bdc964c44801 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-it-possible-to-implement-the-dialog-routine-outcome-monitoring-system-in-a-ps-154907870f8fd3d8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/controlled-evaluation-of-architectural-classifier-and-training-refinements-in-mo-9b6b5ebafa237da4 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/allogenic-platelet-rich-plasma-in-joint-pathologies-a-scoping-review-of-basic-sc-ccb0239c5507a987 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-case-abstracts-presented-at-the-2026-vascular-scientific-sessions-of-th-17356abbdb3b6348 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-immediately-loaded-dental-implants-after-t-77d68a80ff7a1256 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/extended-follow-up-of-botensilimab-plus-balstilimab-in-an-expanded-cohort-of-mic-8871580c40903541 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/distinct-clinical-and-immunologic-patterns-of-interferon-release-assays-implicat-ca8762f7c7c8cfc5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bridging-the-gap-83b94f56544f36fa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-case-of-acute-mania-and-rhabdomyolysis-associated-with-long-term-daily-psilocy-5e9ff14ba01f20d2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/successful-linezolid-based-treatment-of-nocardia-otitidiscaviarum-pneumonia-in-a-75522611e0215260 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-significance-of-i-streptococcus-mitis-i-bacteremia-cb2e2d34699715bf 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-kdigo-2026-clinical-practice-guideline-for-anemia-in-chronic-kidne-a000d38d61280e8d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-of-tuberculosis-preventive-treatment-among-people-receiving-or-about-to-i-749f45684f85b3a3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/plga-nanoparticles-co-loaded-with-resveratrol-and-doxycycline-for-dual-action-pe-939ca4ac398814e2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-probiotic-supplementation-on-psychological-stress-in-healthy-adults-wi-a783c04adb8a175d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/history-of-instruments-and-technology-in-the-clinical-neurosciences-1-a-new-colu-20dd0b4b14d65df6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-renal-replacement-therapy-and-short-term-mortality-in-higher-risk-kdigo-st-24cf7609b60ad216 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/features-and-a-specific-pattern-of-cerebral-perfusion-in-patients-with-lewy-body-355df3a541cce01e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplemental-material-for-an-intervention-based-on-acceptance-and-commitment-the-1d4752ceee3f7ec7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanomaterial-driven-innovation-integrating-catalytic-quinoline-synthesis-and-ant-8cf496cf1a6deeee 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-frontal-qrs-t-angle-and-cardiovascular-disease-a-narrative-review-of-electro-cbbb96a76080672a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/omental-infarction-mimicking-acute-appendicitis-a-case-series-and-systematic-rev-abd897ddb9f816d8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bergen-barbers-a-student-run-haircut-and-grooming-service-to-enhance-empathy-cli-2d783afe88dd1ff0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-profiles-in-fda-approved-new-molecular-entities-2013-2024-a-latent-cl-14b45ca875a5e683 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/using-pre-study-patient-interviews-to-refine-electronic-patient-reported-outcome-180e87a5a4637f62 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/qualitatssicherung-in-der-notfallmedizin-klinische-routinedaten-zur-kontinuierli-9ef90c7e92ec7796 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/laparoscopic-visualisation-of-the-ureters-using-near-infrared-fluorescence-imagi-39abad0ed5393be8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vagus-nerve-stimulation-in-rheumatic-diseases-linking-autonomic-nervous-system-r-fc25d41224e56bfa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/masking-effect-in-the-spanish-spontaneous-reporting-database-fedra-ed8e769df5841923 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-multicenter-randomized-double-blinded-placebo-controlled-phase-2-trial-to-eval-b630ccd85cfbb5fa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shared-output-aptamer-gated-dna-nanodevices-program-nbasparda-trans-cleavage-for-4dd58d1aa5180db7 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-effectiveness-of-sialendoscopy-in-radioactive-iodine-induced-sialadenit-0b3e7d49e37b1880 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/osteomyelitis-epidemiology-classification-pathophysiology-clinical-features-diag-d34e3ed15fd784bd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/atypical-varicella-like-presentation-of-an-imported-mpox-case-in-austria-confirm-17058169ca24c758 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enabling-bioprocess-upscaling-prediction-through-hybrid-modelling-and-transfer-l-49d7f1ddf8c48684 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-free-remission-in-early-peripheral-spondyloarthritis-including-psoriatic-ar-6c81cca77d0e9b70 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-approaches-to-macrophage-activation-syndrome-in-real-life-and-prioriti-102fe79d4968ac65 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831876-a-study-of-ear-nerve-stimulation-to-treat-eye-inflammation-e4573db9274a7699 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831837-evaluation-and-implementation-of-digital-health-ecosystem-in-academi-fdcdcc46b03062f5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831304-randomized-prospective-trial-on-the-cost-effectiveness-of-photon-cou-447db65ba37a6fcc 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831265-a-prospective-randomized-controlled-trial-of-dynamic-fixation-for-co-55d0b71452ea5131 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831226-safety-and-immunogenicity-of-the-recombinant-malaria-vaccines-in-hea-2bcd3e04222cd35a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07831161-safety-and-efficacy-of-autologous-natural-killer-cell-therapy-chank-7684ab7dca353214 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830836-physiotherapy-and-osteopathic-treatment-for-pain-in-the-cervical-and-20384e7f0eeba594 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830355-immunotherapy-plus-anlotinib-after-surgery-for-esophageal-squamous-c-5dd9b5e748bcb337 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07830004-plasmatic-biomarkers-associated-with-short-term-luspatercept-treatme-9f16e1451340d3d9 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07829978-impact-of-diagnostic-and-therapeutic-upper-and-lower-gastrointestina-2f65ffa869894003 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07829809-serum-adropin-as-an-indicator-of-endothelial-dysfunction-and-disease-595c2cf7ea30a7af 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07819747-resources-and-education-for-addressing-chronic-health-reach-5c8914fdbf6ad407 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07793383-adaptive-decision-support-for-addiction-treatment-adapt-serial-rando-c8142426532c5676 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07744152-a-study-to-test-how-well-different-doses-of-bi-3822971-are-tolerated-89d0e68398e8cbf3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07705880-a-novel-clinical-decision-support-tool-to-predict-submucosal-invasiv-73c69ebdf5d8163e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07693751-a-study-to-assess-safety-and-efficacy-of-sot109-in-patients-with-adv-14346cd0d70e71ff 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07616206-cadisegliatin-as-adjunctive-therapy-to-insulin-in-participants-with-5af473b6b56cac59 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07577661-combination-upper-airway-electrical-and-pharmacological-stimulation-898bbd982429e10a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07572240-a-clinical-trial-to-assess-the-effect-of-ap-brain-collagen-peptides-c72f6d5ff4530877 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07495943-effects-of-2-aticyto-complex-and-d-ribose-on-pain-and-clinical-cours-101475d12f61e662 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07266831-a-clinical-study-of-islatravir-and-ulonivirine-for-people-with-hiv-1-eee6bd7200b16053 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262346-the-phase-id-clinical-trial-of-hydronidone-capsules-b492d9ed0ab0ced8 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07248839-a-study-to-assess-the-drug-levels-and-safety-of-bms-986435-in-partic-6bcf7865fc797437 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07237217-guided-group-telehealth-to-deliver-evidence-based-therapeutic-care-t-429f74fb322a7209 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07232030-barostim-enabled-neurohormonal-intervention-for-improving-treatment-b8fbe5404be54fc1 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07211633-a-study-to-evaluate-the-pharmacokinetics-pharmacodynamics-safety-rad-9469e73414b30703 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07194044-metastatic-ewing-s-trial-testing-schedule-enhancement-to-improve-out-15ff028aa39b88b0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07161037-phase-2a-study-of-vx-407-in-participants-with-adpkd-who-have-a-subse-5b834aa1cbecaacd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991738-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iod-8bb88397e09523fd 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06980077-ivonescimab-for-the-treatment-of-thymic-cancer-e1c7cd84dfd11be5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06904066-autologous-t-cells-transduced-with-retroviral-vectors-expressing-tcr-8a1bed717e911091 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06876142-combination-therapy-mirdametinib-and-sirolimus-for-ras-mutated-relap-84e0260330113171 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06843213-teaching-health-resilience-in-a-hospital-setting-a-peer-led-interven-728fcecdf8ae1e52 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06840262-target-muscle-re-innervation-and-regenerative-peripheral-nerve-inter-108eb92d9877d646 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06732401-testing-the-addition-of-azd6738-ceralasertib-to-immunotherapy-to-inc-c8470b82beaaa53e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06549595-a-study-of-surovatamig-azd0486-plus-rituximab-in-previously-untreate-07a6329d0563476d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06473532-text4hf-a-randomized-controlled-trial-of-a-tailored-text-messaging-i-ff5a3fb7b713be45 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06375915-precision-medicine-in-patients-with-unresectable-cholangiocarcinoma-1a7cbd79e9ebb164 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06368388-establishing-personalized-phage-therapy-and-its-comparative-cost-in-0a7ef44acf69cabe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06337318-comparing-rituximab-and-mosunetuzumab-drug-treatments-for-people-wit-f9c0f74dff068b0e 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06326047-a-research-study-comparing-how-well-different-doses-of-the-medicine-f6ec57cf0b2fe58d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06210373-assessment-of-efficacy-and-safety-of-the-use-of-two-eye-gel-products-0073804eb26c0a5c 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06149793-sglt2-inhibitor-therapy-in-cystic-fibrosis-related-diabetes-7fdca58a4e7cc302 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06120244-establishment-of-biobank-of-nasal-epithelium-samples-from-healthy-vo-147d3c56bb9915e2 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06038032-improving-health-behaviours-for-life-after-endometrial-cancer-trial-4118e5d6f2fdb4fe 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06005740-a-phase-1-first-in-human-study-of-torl-4-500-in-patients-with-advanc-c709207ba78bf3a0 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05842330-benefits-of-adhd-treatment-in-detained-people-06046ff851a60e9f 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05383274-optilume-post-approval-clinical-evaluation-of-andrology-parameters-bc64816ab9b77eb5 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05041309-long-term-follow-up-study-after-gene-modified-cell-treatment-in-kite-de88c2de50133c8a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04984005-the-interaction-and-regulation-mechanism-of-different-exercise-patte-093e891995b9f987 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04512209-characterization-of-biophysical-stromal-properties-in-human-cancer-t-4b671ba1b3860be3 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04359732-assessment-of-response-to-ncrt-for-gej-cancer-using-a-fully-integrat-8c8a048767bc00f6 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04018092-the-revitalize-study-in-older-adults-at-risk-for-alzheimer-s-disease-dbe5d764e71a0caa 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03226704-leukapheresis-for-car-or-adoptive-cell-therapy-manufacturing-8859eb3be74c76ca 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03223103-safety-and-immunogenicity-of-personalized-genomic-vaccine-and-tumor-f248e56d06f14a0a 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02003222-combination-chemotherapy-with-or-without-blinatumomab-in-treating-pa-489f33c4c086296d 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01496625-national-eye-institute-biorepository-for-retinal-diseases-99078260bf2b6307 2026-09-21T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-halts-trading-ahead-of-phase-3-trial-update-aa25a9abde83efd3 2026-09-20T23:48:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/click-estock-aribio-holdings-set-to-announce-ar1001-phase-3-results-rapid-commer-cc4b1439181b24d5 2026-09-20T23:37:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/expert-team-to-drive-improvements-in-cancer-care-417d32b858766792 2026-09-20T23:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311 2026-09-20T22:53:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998 2026-09-20T22:25:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/battles-in-u-s-war-on-cancer-being-waged-at-white-plains-hospital-d5ac453bc8b5b463 2026-09-20T21:37:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-escalates-warnings-on-compounded-glp-1-drugs-but-its-own-data-reveal-importa-784876c401fb6a60 2026-09-20T20:22:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-bet-on-biology-why-one-modality-is-never-enough-in-lung-cancer-22ddcff0c7b1d6de 2026-09-20T19:01:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-the-trial-fails-was-it-the-drug-or-the-design-7d9fc4711d67aecd 2026-09-20T19:01:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/liminal-biosciences-stock-remains-without-fresh-data-in-latest-search-window-e69750d05b62c05d 2026-09-20T18:36:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/igm-biosciences-stock-trades-quietly-amid-lack-of-fresh-data-7fcb87bd5c7cfbbd 2026-09-20T17:53:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drugs-karnataka-fda-cancels-16-drug-licences-of-retailers-wholesalers-483f672ee324efee 2026-09-20T17:46:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-cancels-16-drug-licences-of-retailers-wholesalers-over-spurious-medici-2c63099044d2094e 2026-09-20T16:43:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-real-start-of-every-biotech-story-is-not-a-lab-but-the-funding-decision-c8c47d90798c3214 2026-09-20T16:42:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/counterfeit-drug-racket-karnataka-fda-cancels-licences-of-16-firms-suspends-eigh-75a62da78792156d 2026-09-20T16:27:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/k-taka-fda-cancels-16-drug-licences-of-retailers-wholesalers-c3da9512d4ad2b56 2026-09-20T16:19:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-bidadi-farmhouse-rs-5-crore-stock-seized-37c1c944ca0872f9 2026-09-20T16:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-s-biotech-start-ups-need-patient-capital-to-drive-novel-drug-innovation-in-7b639daf4e308b1a 2026-09-20T16:03:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-reviewing-contraceptives-tied-to-meningioma-risk-e58870d2131fdd90 2026-09-20T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bidadi-fake-drug-racket-fallout-widens-karnataka-fda-cancels-16-licences-suspend-f5da6067ed6d5f34 2026-09-20T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cheap-drugs-fake-labels-non-functional-qr-codes-karnataka-fda-cancels-16-licence-30805af09704bb40 2026-09-20T15:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-suspends-license-of-pfizer-depot-7-other-firms-5a01456374a081c9 2026-09-20T15:39:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/novocure-nvcr-breaks-out-on-q2-2026-earnings-optune-pax-driving-recovery-d29aa8bbd69d100a 2026-09-20T15:34:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cancels-16-suspends-eight-drug-licences-in-karnataka-india-news-ba30705170e35c28 2026-09-20T15:25:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/sartorius-stedim-stock-holds-steady-as-investors-digest-recent-results-357e977aebe6ec21 2026-09-20T15:08:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-finds-no-neurodevelopmental-risk-in-prenatal-covid-19-except-speech-60978aa7141468f4 2026-09-20T15:06:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-drug-racket-case-why-did-karnataka-fda-take-action-against-pfizer-and-other-c891e75d1209a28e 2026-09-20T14:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-3e00c4b5d346cd8c 2026-09-20T14:41:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-16-licences-cancelled-over-suspected-fake-drug-supply-0e40f8f1294379fe 2026-09-20T14:36:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-near-fair-value-as-valuation-debate-int-4a13daa556aa57de 2026-09-20T14:28:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-is-drawing-attention-to-west-pharmaceutical-services-wst-92b5c124882ba4d9 2026-09-20T14:07:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerating-digital-transformation-in-the-pharmaceutical-sector-61a20ba6a4cf5dbb 2026-09-20T14:06:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-society-calls-for-stronger-drug-regulation-f2db6216a77cc7af 2026-09-20T14:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-biotech-firm-innata-bio-moves-headquarters-to-philadelphia-s-lilly-gateway-la-c364a610699ace50 2026-09-20T14:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/karnataka-fda-cancels-16-pharmacy-licences-over-spurious-drug-racket-f06b08fa08cf993b 2026-09-20T13:57:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/fake-drugs-karnataka-cancels-16-licenses-suspends-8-including-that-of-pfizer-dep-72248dc68285db68 2026-09-20T13:56:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investors-dumped-ionis-pharmaceuticals-stock-but-wall-street-hasn-t-budged-from-ff4660a6a8ea5bfa 2026-09-20T13:55:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-farmhouse-in-karnataka-s-bidadi-24-pharma-licence-55071d8965d7b532 2026-09-20T13:51:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-ultragenyx-pharmaceutical-rare-cheap-on-fayuvi-fda-approval-ba65c38fdef312f2 2026-09-20T13:44:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/gh-research-gets-fda-clearance-to-start-phase-3-trial-for-new-depression-treatme-1999373cc534630c 2026-09-20T13:34:25.000Z weekly 0.7